Page last updated: 2024-12-07

fingolimod

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

Fingolimod is a sphingosine 1-phosphate receptor modulator that is used to treat relapsing forms of multiple sclerosis. It is synthesized as a derivative of myriocin, a natural product isolated from the fungus Isaria sinclairii. Fingolimod works by preventing lymphocytes from leaving lymph nodes and entering the central nervous system, thus reducing inflammation and damage to the myelin sheath. It is studied because it has been shown to be effective in reducing the frequency and severity of relapses in multiple sclerosis, and it has a favorable safety profile. Fingolimod is an important drug for the treatment of multiple sclerosis because it provides a long-term treatment option with a relatively low risk of serious side effects.'

fingolimod : An aminodiol that consists of propane-1,3-diol having amino and 2-(4-octylphenyl)ethyl substituents at the 2-position. It is a sphingosine 1-phosphate receptor modulator used for the treatment of relapsing-remitting multiple sclerosis. A prodrug, fingolimod is phosphorylated by sphingosine kinase to active metabolite fingolimod-phosphate, a structural analogue of sphingosine 1-phosphate. [Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Cross-References

ID SourceID
PubMed CID107970
CHEMBL ID314854
CHEBI ID63115
SCHEMBL ID7445
MeSH IDM0259277

Synonyms (61)

Synonym
CHEMBL314854 ,
chebi:63115 ,
fingolimod
gtpl2407
2-amino-2-(4-octylphenethyl)propane-1,3-diol
2-(4-octylphenethyl)-2-aminopropane-1,3-diol
2-amino-2-(4-octylphenyl)ethylpropane-1,3-diol
bdbm50158336
2-amino-2-[2-(4-octyl-phenyl)-ethyl]-propane-1,3-diol
162359-55-9
2-amino-2-(2-(4-octylphenyl)ethyl)propane-1,3-diol
FT-0660847
2-amino-2-[2-(4-octylphenyl)ethyl]propane-1,3-diol
NCGC00188399-01
D10001 ,
fingolimod (inn)
fingolimodum
AKOS015999594
fingolimod [inn]
1,3-propanediol, 2-amino-2-(2-(4-octylphenyl)ethyl)-
unii-3qn8byn5qf
3qn8byn5qf ,
NCGC00188399-03
S5950
2-amino-2-[2-(4-octylphenyl)ethyl]-1,3-propanediol
fingolimod [orange book]
fingolimod [vandf]
fingolimod [mart.]
fingolimod [mi]
DB05286
fingolimod [who-dd]
DB08868
HY-11063
KKGQTZUTZRNORY-UHFFFAOYSA-N
2-amino-2-hydroxymethyl-4-(4-(octyl)phenyl)butanol
2-amino-2-(2-(4-octylphenyl)ethyl)-1,3-propanediol
SCHEMBL7445
c19h33no2
2-amino-2-[2-(4-octylphenyl)ethyl]-1,3-propandiol
AC-25899
DTXSID40167363 ,
STL445699
1,3-propanediol, 2-amino-2-[2-(4-octylphenyl)ethyl]-
AS-68987
NCGC00188399-04
BCP05969
Q425137
AMY22173
BRD-K88025533-003-01-7
HMS3743O13
NCGC00188399-06
D70458
NCGC00188399-16
nsc755643
nsc-755643
BF164460
fingolimod- bio-x
EN300-18802383
fingolimod (mart.)
dtxcid0089854
l04aa27

Research Excerpts

Overview

Fingolimod (FTY720) is an orally active immunomodulatory drug that has been used for the treatment of relapsing-remitting multiple sclerosis.

ExcerptReferenceRelevance
"Fingolimod (FTY720) is an orally active immunomodulatory drug that has been used for the treatment of relapsing-remitting multiple sclerosis."( Computer design, synthesis, and bioactivity analyses of drugs like fingolimod used in the treatment of multiple sclerosis.
Akdemir, A; Dişli, A; Doyduk, D; Şen, A; Turgut, GÇ; Yavuz, S; Yıldırır, Y, 2017
)
1.41

Bioavailability

ExcerptReferenceRelevance
" The alcohol 10 demonstrated good oral bioavailability and rapid in vivo conversion to 10-P."( Discovery of Clinical Candidate GSK1842799 As a Selective S1P1 Receptor Agonist (Prodrug) for Multiple Sclerosis.
Bernier, SG; Deng, H; Doyle, E; Evindar, G; Lorusso, J; Morgan, BA; Westlin, WF, 2013
)
0.39
"Cell membrane permeability is an important determinant for oral absorption and bioavailability of a drug molecule."( Highly predictive and interpretable models for PAMPA permeability.
Jadhav, A; Kerns, E; Nguyen, K; Shah, P; Sun, H; Xu, X; Yan, Z; Yu, KR, 2017
)
0.46
" This ultimately led to the discovery of 16, an orally bioavailable compound that showed efficacy in murine experimental autoimmune encephalomyelitis (EAE), a preclinical model of multiple sclerosis."( Design and Synthesis of a Novel Series of Orally Bioavailable, CNS-Penetrant, Isoform Selective Phosphoinositide 3-Kinase γ (PI3Kγ) Inhibitors with Potential for the Treatment of Multiple Sclerosis (MS).
Aronov, AM; Bandarage, UK; Cao, J; Chin, EY; Collier, PN; Come, JH; Damagnez, V; Davies, RJ; Deininger, D; Doran, JD; Dworakowski, W; Grey, R; Griffith, JP; Henderson, JA; Jacobs, MD; Khare-Pandit, S; Krueger, EB; Le Tiran, A; Liang, J; Liao, Y; Lowe, DB; Mahajan, S; Messersmith, D; Moody, CS; Nanthakumar, S; O'Dowd, H; Pierce, AC; Sizensky, E; Wang, J; Xu, J, 2018
)
0.48
"The ATP-binding cassette transporter P-glycoprotein (P-gp) is known to limit both brain penetration and oral bioavailability of many chemotherapy drugs."( A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
Ambudkar, SV; Brimacombe, KR; Chen, L; Gottesman, MM; Guha, R; Hall, MD; Klumpp-Thomas, C; Lee, OW; Lee, TD; Lusvarghi, S; Robey, RW; Shen, M; Tebase, BG, 2019
)
0.51

Dosage Studied

ExcerptRelevanceReference
" 31 induces profound reduction of peripheral T cell numbers after oral dosage and confers pronounced protection in a rat model of multiple sclerosis."( Orally active 7-substituted (4-benzylphthalazin-1-yl)-2-methylpiperazin-1-yl]nicotinonitriles as active-site inhibitors of sphingosine 1-phosphate lyase for the treatment of multiple sclerosis.
Beerli, C; Bergsdorf, C; Billich, A; Braendlin, N; Oberhauser, B; Schubart, A; Srinivas, H; Weiler, S, 2014
)
0.4
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Roles (5)

RoleDescription
immunosuppressive agentAn agent that suppresses immune function by one of several mechanisms of action. Classical cytotoxic immunosuppressants act by inhibiting DNA synthesis. Others may act through activation of T-cells or by inhibiting the activation of helper cells. In addition, an immunosuppressive agent is a role played by a compound which is exhibited by a capability to diminish the extent and/or voracity of an immune response.
prodrugA compound that, on administration, must undergo chemical conversion by metabolic processes before becoming the pharmacologically active drug for which it is a prodrug.
antineoplastic agentA substance that inhibits or prevents the proliferation of neoplasms.
sphingosine-1-phosphate receptor agonistAn agonist that binds to and activates sphingosine 1-phosphate receptors.
CB1 receptor antagonistAn antagonist that binds to and deactivates type 1 cannabinoid receptors.
[role information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Drug Classes (2)

ClassDescription
aminodiolAn amino alcohol having two hydroxy functional groups.
primary amino compoundA compound formally derived from ammonia by replacing one hydrogen atom by an organyl group.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Protein Targets (13)

Potency Measurements

ProteinTaxonomyMeasurementAverage (µ)Min (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Fumarate hydrataseHomo sapiens (human)Potency9.34950.00308.794948.0869AID1347053
PPM1D proteinHomo sapiens (human)Potency23.36170.00529.466132.9993AID1347411
EWS/FLI fusion proteinHomo sapiens (human)Potency21.00050.001310.157742.8575AID1259252; AID1259253; AID1259255; AID1259256
polyproteinZika virusPotency9.34950.00308.794948.0869AID1347053
Interferon betaHomo sapiens (human)Potency23.36170.00339.158239.8107AID1347411
Spike glycoproteinSevere acute respiratory syndrome-related coronavirusPotency39.81070.009610.525035.4813AID1479145
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Inhibition Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Sphingosine 1-phosphate receptor 2Homo sapiens (human)IC50 (µMol)10.00000.00020.10421.1000AID282268
Sphingosine 1-phosphate receptor 4Homo sapiens (human)IC50 (µMol)10.00000.00100.10680.4170AID282270
Sphingosine 1-phosphate receptor 1Homo sapiens (human)IC50 (µMol)0.72190.00000.08550.8400AID1896040; AID282267
Sphingosine 1-phosphate receptor 3Homo sapiens (human)IC50 (µMol)10.00000.00000.00450.0230AID282269
Sphingosine 1-phosphate receptor 5Homo sapiens (human)IC50 (µMol)2.10000.00050.83884.6000AID282271
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Activation Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Sphingosine 1-phosphate receptor 2Homo sapiens (human)EC50 (µMol)10.00000.00070.36512.8530AID240248
Sphingosine 1-phosphate receptor 4Homo sapiens (human)EC50 (µMol)5.00020.00010.26263.2500AID1054253; AID240250
Sphingosine 1-phosphate receptor 1Homo sapiens (human)EC50 (µMol)4.00190.00000.17597.8700AID1054255; AID1271835; AID1370504; AID240247; AID642403
Sphingosine 1-phosphate receptor 3Homo sapiens (human)EC50 (µMol)5.62870.00010.30925.0000AID1054254; AID1271836; AID1370505; AID240249
Sphingosine 1-phosphate receptor 5Homo sapiens (human)EC50 (µMol)4.38750.00020.13653.1623AID1054252; AID1370503; AID240251
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Biological Processes (93)

Processvia Protein(s)Taxonomy
G protein-coupled receptor signaling pathwaySphingosine 1-phosphate receptor 2Homo sapiens (human)
sphingosine-1-phosphate receptor signaling pathwaySphingosine 1-phosphate receptor 2Homo sapiens (human)
positive regulation of cell population proliferationSphingosine 1-phosphate receptor 2Homo sapiens (human)
positive regulation of peptidyl-threonine phosphorylationSphingosine 1-phosphate receptor 2Homo sapiens (human)
actin cytoskeleton organizationSphingosine 1-phosphate receptor 2Homo sapiens (human)
filopodium assemblySphingosine 1-phosphate receptor 2Homo sapiens (human)
excitatory postsynaptic potentialSphingosine 1-phosphate receptor 2Homo sapiens (human)
negative regulation of excitatory postsynaptic potentialSphingosine 1-phosphate receptor 2Homo sapiens (human)
positive regulation of establishment of endothelial barrierSphingosine 1-phosphate receptor 2Homo sapiens (human)
regulation of metabolic processSphingosine 1-phosphate receptor 2Homo sapiens (human)
adenylate cyclase-activating G protein-coupled receptor signaling pathwaySphingosine 1-phosphate receptor 2Homo sapiens (human)
luteinizationSphingosine-1-phosphate lyase 1Homo sapiens (human)
vasculogenesisSphingosine-1-phosphate lyase 1Homo sapiens (human)
kidney developmentSphingosine-1-phosphate lyase 1Homo sapiens (human)
fatty acid metabolic processSphingosine-1-phosphate lyase 1Homo sapiens (human)
ceramide metabolic processSphingosine-1-phosphate lyase 1Homo sapiens (human)
spermatogenesisSphingosine-1-phosphate lyase 1Homo sapiens (human)
androgen metabolic processSphingosine-1-phosphate lyase 1Homo sapiens (human)
estrogen metabolic processSphingosine-1-phosphate lyase 1Homo sapiens (human)
post-embryonic developmentSphingosine-1-phosphate lyase 1Homo sapiens (human)
fibroblast migrationSphingosine-1-phosphate lyase 1Homo sapiens (human)
hemopoiesisSphingosine-1-phosphate lyase 1Homo sapiens (human)
sphingolipid catabolic processSphingosine-1-phosphate lyase 1Homo sapiens (human)
Leydig cell differentiationSphingosine-1-phosphate lyase 1Homo sapiens (human)
regulation of multicellular organism growthSphingosine-1-phosphate lyase 1Homo sapiens (human)
platelet-derived growth factor receptor signaling pathwaySphingosine-1-phosphate lyase 1Homo sapiens (human)
skeletal system morphogenesisSphingosine-1-phosphate lyase 1Homo sapiens (human)
roof of mouth developmentSphingosine-1-phosphate lyase 1Homo sapiens (human)
face morphogenesisSphingosine-1-phosphate lyase 1Homo sapiens (human)
apoptotic signaling pathwaySphingosine-1-phosphate lyase 1Homo sapiens (human)
sphingosine-1-phosphate receptor signaling pathwaySphingosine 1-phosphate receptor 4Homo sapiens (human)
immune responseSphingosine 1-phosphate receptor 4Homo sapiens (human)
G protein-coupled receptor signaling pathwaySphingosine 1-phosphate receptor 4Homo sapiens (human)
activation of phospholipase C activitySphingosine 1-phosphate receptor 4Homo sapiens (human)
positive regulation of cytosolic calcium ion concentrationSphingosine 1-phosphate receptor 4Homo sapiens (human)
regulation of metabolic processSphingosine 1-phosphate receptor 4Homo sapiens (human)
adenylate cyclase-activating G protein-coupled receptor signaling pathwaySphingosine 1-phosphate receptor 4Homo sapiens (human)
cell surface receptor signaling pathway via JAK-STATInterferon betaHomo sapiens (human)
response to exogenous dsRNAInterferon betaHomo sapiens (human)
B cell activation involved in immune responseInterferon betaHomo sapiens (human)
cell surface receptor signaling pathwayInterferon betaHomo sapiens (human)
cell surface receptor signaling pathway via JAK-STATInterferon betaHomo sapiens (human)
response to virusInterferon betaHomo sapiens (human)
positive regulation of autophagyInterferon betaHomo sapiens (human)
cytokine-mediated signaling pathwayInterferon betaHomo sapiens (human)
natural killer cell activationInterferon betaHomo sapiens (human)
positive regulation of peptidyl-serine phosphorylation of STAT proteinInterferon betaHomo sapiens (human)
cellular response to interferon-betaInterferon betaHomo sapiens (human)
B cell proliferationInterferon betaHomo sapiens (human)
negative regulation of viral genome replicationInterferon betaHomo sapiens (human)
innate immune responseInterferon betaHomo sapiens (human)
positive regulation of innate immune responseInterferon betaHomo sapiens (human)
regulation of MHC class I biosynthetic processInterferon betaHomo sapiens (human)
negative regulation of T cell differentiationInterferon betaHomo sapiens (human)
positive regulation of transcription by RNA polymerase IIInterferon betaHomo sapiens (human)
defense response to virusInterferon betaHomo sapiens (human)
type I interferon-mediated signaling pathwayInterferon betaHomo sapiens (human)
neuron cellular homeostasisInterferon betaHomo sapiens (human)
cellular response to exogenous dsRNAInterferon betaHomo sapiens (human)
cellular response to virusInterferon betaHomo sapiens (human)
negative regulation of Lewy body formationInterferon betaHomo sapiens (human)
negative regulation of T-helper 2 cell cytokine productionInterferon betaHomo sapiens (human)
positive regulation of apoptotic signaling pathwayInterferon betaHomo sapiens (human)
response to exogenous dsRNAInterferon betaHomo sapiens (human)
B cell differentiationInterferon betaHomo sapiens (human)
natural killer cell activation involved in immune responseInterferon betaHomo sapiens (human)
adaptive immune responseInterferon betaHomo sapiens (human)
T cell activation involved in immune responseInterferon betaHomo sapiens (human)
humoral immune responseInterferon betaHomo sapiens (human)
blood vessel maturationSphingosine 1-phosphate receptor 1Homo sapiens (human)
cardiac muscle tissue growth involved in heart morphogenesisSphingosine 1-phosphate receptor 1Homo sapiens (human)
sphingosine-1-phosphate receptor signaling pathwaySphingosine 1-phosphate receptor 1Homo sapiens (human)
chemotaxisSphingosine 1-phosphate receptor 1Homo sapiens (human)
cell adhesionSphingosine 1-phosphate receptor 1Homo sapiens (human)
G protein-coupled receptor signaling pathwaySphingosine 1-phosphate receptor 1Homo sapiens (human)
adenylate cyclase-inhibiting G protein-coupled receptor signaling pathwaySphingosine 1-phosphate receptor 1Homo sapiens (human)
phospholipase C-activating G protein-coupled receptor signaling pathwaySphingosine 1-phosphate receptor 1Homo sapiens (human)
brain developmentSphingosine 1-phosphate receptor 1Homo sapiens (human)
cell population proliferationSphingosine 1-phosphate receptor 1Homo sapiens (human)
cell migrationSphingosine 1-phosphate receptor 1Homo sapiens (human)
transmission of nerve impulseSphingosine 1-phosphate receptor 1Homo sapiens (human)
lamellipodium assemblySphingosine 1-phosphate receptor 1Homo sapiens (human)
actin cytoskeleton organizationSphingosine 1-phosphate receptor 1Homo sapiens (human)
regulation of cell adhesionSphingosine 1-phosphate receptor 1Homo sapiens (human)
neuron differentiationSphingosine 1-phosphate receptor 1Homo sapiens (human)
positive regulation of cell migrationSphingosine 1-phosphate receptor 1Homo sapiens (human)
regulation of bone mineralizationSphingosine 1-phosphate receptor 1Homo sapiens (human)
leukocyte chemotaxisSphingosine 1-phosphate receptor 1Homo sapiens (human)
regulation of bone resorptionSphingosine 1-phosphate receptor 1Homo sapiens (human)
endothelial cell differentiationSphingosine 1-phosphate receptor 1Homo sapiens (human)
positive regulation of transcription by RNA polymerase IISphingosine 1-phosphate receptor 1Homo sapiens (human)
positive regulation of smooth muscle cell proliferationSphingosine 1-phosphate receptor 1Homo sapiens (human)
positive regulation of positive chemotaxisSphingosine 1-phosphate receptor 1Homo sapiens (human)
negative regulation of stress fiber assemblySphingosine 1-phosphate receptor 1Homo sapiens (human)
heart trabecula morphogenesisSphingosine 1-phosphate receptor 1Homo sapiens (human)
T cell migrationSphingosine 1-phosphate receptor 1Homo sapiens (human)
angiogenesisSphingosine 1-phosphate receptor 1Homo sapiens (human)
regulation of metabolic processSphingosine 1-phosphate receptor 1Homo sapiens (human)
adenylate cyclase-activating G protein-coupled receptor signaling pathwaySphingosine 1-phosphate receptor 1Homo sapiens (human)
sphingosine-1-phosphate receptor signaling pathwaySphingosine 1-phosphate receptor 3Homo sapiens (human)
inflammatory responseSphingosine 1-phosphate receptor 3Homo sapiens (human)
G protein-coupled receptor signaling pathwaySphingosine 1-phosphate receptor 3Homo sapiens (human)
adenylate cyclase-inhibiting G protein-coupled receptor signaling pathwaySphingosine 1-phosphate receptor 3Homo sapiens (human)
positive regulation of cytosolic calcium ion concentrationSphingosine 1-phosphate receptor 3Homo sapiens (human)
Notch signaling pathwaySphingosine 1-phosphate receptor 3Homo sapiens (human)
positive regulation of cell population proliferationSphingosine 1-phosphate receptor 3Homo sapiens (human)
anatomical structure morphogenesisSphingosine 1-phosphate receptor 3Homo sapiens (human)
regulation of interleukin-1 beta productionSphingosine 1-phosphate receptor 3Homo sapiens (human)
negative regulation of establishment of endothelial barrierSphingosine 1-phosphate receptor 3Homo sapiens (human)
adenylate cyclase-activating G protein-coupled receptor signaling pathwaySphingosine 1-phosphate receptor 3Homo sapiens (human)
regulation of metabolic processSphingosine 1-phosphate receptor 3Homo sapiens (human)
sphingosine-1-phosphate receptor signaling pathwaySphingosine 1-phosphate receptor 5Homo sapiens (human)
regulation of neuron differentiationSphingosine 1-phosphate receptor 5Homo sapiens (human)
regulation of metabolic processSphingosine 1-phosphate receptor 5Homo sapiens (human)
adenylate cyclase-activating G protein-coupled receptor signaling pathwaySphingosine 1-phosphate receptor 5Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Molecular Functions (14)

Processvia Protein(s)Taxonomy
G protein-coupled receptor bindingSphingosine 1-phosphate receptor 2Homo sapiens (human)
G protein-coupled receptor activitySphingosine 1-phosphate receptor 2Homo sapiens (human)
integrin bindingSphingosine 1-phosphate receptor 2Homo sapiens (human)
protein bindingSphingosine 1-phosphate receptor 2Homo sapiens (human)
lipid bindingSphingosine 1-phosphate receptor 2Homo sapiens (human)
G protein-coupled peptide receptor activitySphingosine 1-phosphate receptor 2Homo sapiens (human)
sphingosine-1-phosphate receptor activitySphingosine 1-phosphate receptor 2Homo sapiens (human)
protein bindingSphingosine-1-phosphate lyase 1Homo sapiens (human)
sphinganine-1-phosphate aldolase activitySphingosine-1-phosphate lyase 1Homo sapiens (human)
pyridoxal phosphate bindingSphingosine-1-phosphate lyase 1Homo sapiens (human)
protein bindingSphingosine 1-phosphate receptor 4Homo sapiens (human)
lipid bindingSphingosine 1-phosphate receptor 4Homo sapiens (human)
sphingosine-1-phosphate receptor activitySphingosine 1-phosphate receptor 4Homo sapiens (human)
G protein-coupled receptor activitySphingosine 1-phosphate receptor 4Homo sapiens (human)
cytokine activityInterferon betaHomo sapiens (human)
cytokine receptor bindingInterferon betaHomo sapiens (human)
type I interferon receptor bindingInterferon betaHomo sapiens (human)
protein bindingInterferon betaHomo sapiens (human)
chloramphenicol O-acetyltransferase activityInterferon betaHomo sapiens (human)
G protein-coupled receptor bindingSphingosine 1-phosphate receptor 1Homo sapiens (human)
G protein-coupled receptor activitySphingosine 1-phosphate receptor 1Homo sapiens (human)
protein bindingSphingosine 1-phosphate receptor 1Homo sapiens (human)
sphingosine-1-phosphate receptor activitySphingosine 1-phosphate receptor 1Homo sapiens (human)
sphingolipid bindingSphingosine 1-phosphate receptor 1Homo sapiens (human)
integrin bindingSphingosine 1-phosphate receptor 3Homo sapiens (human)
protein bindingSphingosine 1-phosphate receptor 3Homo sapiens (human)
lipid bindingSphingosine 1-phosphate receptor 3Homo sapiens (human)
sphingosine-1-phosphate receptor activitySphingosine 1-phosphate receptor 3Homo sapiens (human)
G protein-coupled receptor activitySphingosine 1-phosphate receptor 3Homo sapiens (human)
protein bindingSphingosine 1-phosphate receptor 5Homo sapiens (human)
sphingosine-1-phosphate receptor activitySphingosine 1-phosphate receptor 5Homo sapiens (human)
G protein-coupled receptor activitySphingosine 1-phosphate receptor 5Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Ceullar Components (14)

Processvia Protein(s)Taxonomy
plasma membraneSphingosine 1-phosphate receptor 2Homo sapiens (human)
postsynapseSphingosine 1-phosphate receptor 2Homo sapiens (human)
plasma membraneSphingosine 1-phosphate receptor 2Homo sapiens (human)
cytoplasmSphingosine 1-phosphate receptor 2Homo sapiens (human)
endoplasmic reticulumSphingosine-1-phosphate lyase 1Homo sapiens (human)
endoplasmic reticulum membraneSphingosine-1-phosphate lyase 1Homo sapiens (human)
endoplasmic reticulumSphingosine-1-phosphate lyase 1Homo sapiens (human)
mitochondrionSphingosine 1-phosphate receptor 4Homo sapiens (human)
plasma membraneSphingosine 1-phosphate receptor 4Homo sapiens (human)
plasma membraneSphingosine 1-phosphate receptor 4Homo sapiens (human)
cytoplasmSphingosine 1-phosphate receptor 4Homo sapiens (human)
extracellular spaceInterferon betaHomo sapiens (human)
extracellular regionInterferon betaHomo sapiens (human)
nucleoplasmSphingosine 1-phosphate receptor 1Homo sapiens (human)
endosomeSphingosine 1-phosphate receptor 1Homo sapiens (human)
plasma membraneSphingosine 1-phosphate receptor 1Homo sapiens (human)
external side of plasma membraneSphingosine 1-phosphate receptor 1Homo sapiens (human)
intracellular membrane-bounded organelleSphingosine 1-phosphate receptor 1Homo sapiens (human)
membrane raftSphingosine 1-phosphate receptor 1Homo sapiens (human)
plasma membraneSphingosine 1-phosphate receptor 1Homo sapiens (human)
cytoplasmSphingosine 1-phosphate receptor 1Homo sapiens (human)
virion membraneSpike glycoproteinSevere acute respiratory syndrome-related coronavirus
plasma membraneSphingosine 1-phosphate receptor 3Homo sapiens (human)
cytoplasmSphingosine 1-phosphate receptor 3Homo sapiens (human)
plasma membraneSphingosine 1-phosphate receptor 3Homo sapiens (human)
plasma membraneSphingosine 1-phosphate receptor 5Homo sapiens (human)
cytoplasmSphingosine 1-phosphate receptor 5Homo sapiens (human)
plasma membraneSphingosine 1-phosphate receptor 5Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Bioassays (390)

Assay IDTitleYearJournalArticle
AID1334092Effect on MAG mRNA expression in human U118MG cells at EC10 by qPCR method relative to beta-actin2017Bioorganic & medicinal chemistry, 01-15, Volume: 25, Issue:2
Computer design, synthesis, and bioactivity analyses of drugs like fingolimod used in the treatment of multiple sclerosis.
AID1422490Cytotoxicity against mouse FL5.12 cells after 48 hrs by DAPI or propidium iodide staining-based flow cytometric analysis2018European journal of medicinal chemistry, Nov-05, Volume: 159In search of constrained FTY720 and phytosphingosine analogs as dual acting anticancer agents targeting metabolic and epigenetic pathways.
AID1334146Effect on AGT mRNA expression in human U118MG cells at EC10 by qPCR method relative to beta-actin2017Bioorganic & medicinal chemistry, 01-15, Volume: 25, Issue:2
Computer design, synthesis, and bioactivity analyses of drugs like fingolimod used in the treatment of multiple sclerosis.
AID1280942Half life in human2016Journal of medicinal chemistry, Feb-11, Volume: 59, Issue:3
Discovery of Tetrahydropyrazolopyridine as Sphingosine 1-Phosphate Receptor 3 (S1P3)-Sparing S1P1 Agonists Active at Low Oral Doses.
AID1334015Cytotoxicity against human U118MG cells measured after 24 hrs by crystal-violet staining based assay2017Bioorganic & medicinal chemistry, 01-15, Volume: 25, Issue:2
Computer design, synthesis, and bioactivity analyses of drugs like fingolimod used in the treatment of multiple sclerosis.
AID1334180Effect on FASLG mRNA expression in human SK-N-SH cells at EC10 by qPCR method relative to beta-actin2017Bioorganic & medicinal chemistry, 01-15, Volume: 25, Issue:2
Computer design, synthesis, and bioactivity analyses of drugs like fingolimod used in the treatment of multiple sclerosis.
AID1334032Effect on IL6 mRNA expression in human SH-SY5Y cells at EC10 by qPCR method relative to beta-actin2017Bioorganic & medicinal chemistry, 01-15, Volume: 25, Issue:2
Computer design, synthesis, and bioactivity analyses of drugs like fingolimod used in the treatment of multiple sclerosis.
AID1185037Neuroprotective activity in mouse MN9D cells assessed as blocking of TNF-alpha associated toxicity at 0.16 uM after 72 hrs by Trypan blue staining2014ACS medicinal chemistry letters, Jul-10, Volume: 5, Issue:7
Novel FTY720-Based Compounds Stimulate Neurotrophin Expression and Phosphatase Activity in Dopaminergic Cells.
AID1300084Reduction in IL2 gene expression in SCID mouse with CD45RBhiCD4+ T-cell transfer-induced colitis model of inflammatory bowel disease at 5 mg/kg, po dosed every other day for 5 weeks by RT-PCR method2016ACS medicinal chemistry letters, Mar-10, Volume: 7, Issue:3
Identification and Preclinical Pharmacology of BMS-986104: A Differentiated S1P1 Receptor Modulator in Clinical Trials.
AID1334022Effect on PMP22 mRNA expression in human SH-SY5Y cells at EC10 by qPCR method relative to beta-actin2017Bioorganic & medicinal chemistry, 01-15, Volume: 25, Issue:2
Computer design, synthesis, and bioactivity analyses of drugs like fingolimod used in the treatment of multiple sclerosis.
AID282270Displacement of [33P]sphingosine 1 phosphate from human S1P4 receptor expressed in CHO cells2004Journal of medicinal chemistry, Dec-30, Volume: 47, Issue:27
A rational utilization of high-throughput screening affords selective, orally bioavailable 1-benzyl-3-carboxyazetidine sphingosine-1-phosphate-1 receptor agonists.
AID1300083Reduction in body weight loss in SCID mouse with CD45RBhiCD4+ T-cell transfer-induced colitis model of inflammatory bowel disease at 1 mg/kg, po dosed daily for 5 weeks2016ACS medicinal chemistry letters, Mar-10, Volume: 7, Issue:3
Identification and Preclinical Pharmacology of BMS-986104: A Differentiated S1P1 Receptor Modulator in Clinical Trials.
AID777396Cytotoxicity against Ph-positive human BV173 cells after 72 hrs by vital dye exclusion/flow cytometric analysis2013ACS medicinal chemistry letters, Oct-10, Volume: 4, Issue:10
Design, Synthesis, and Anti-leukemic Activity of Stereochemically Defined Constrained Analogs of FTY720 (Gilenya).
AID1532403Immunosuppressive activity in human assessed as decrease in peripheral blood lymphocyte count at 0.1 mg/kg, po qd relative to control2018Bioorganic & medicinal chemistry letters, 12-15, Volume: 28, Issue:23-24
An update on sphingosine-1-phosphate receptor 1 modulators.
AID1334014Cytotoxicity against human SK-N-SH cells measured after 24 hrs by crystal-violet staining based assay2017Bioorganic & medicinal chemistry, 01-15, Volume: 25, Issue:2
Computer design, synthesis, and bioactivity analyses of drugs like fingolimod used in the treatment of multiple sclerosis.
AID596410Antiproliferative activity against human MDA-MB-231 cells assessed as growth inhibition after 78 hrs by WST-1 assay2011Journal of natural products, Apr-25, Volume: 74, Issue:4
Fingolimod (FTY720): a recently approved multiple sclerosis drug based on a fungal secondary metabolite.
AID1627822Induction of vacuolation in mouse FL5.12A cells assessed as vacuolation score at 2.5 uM measured at 3 hrs by fluorescence microscopic analysis2016Bioorganic & medicinal chemistry, 09-15, Volume: 24, Issue:18
Effects of stereochemistry, saturation, and hydrocarbon chain length on the ability of synthetic constrained azacyclic sphingolipids to trigger nutrient transporter down-regulation, vacuolation, and cell death.
AID1334221Effect on GRM1 mRNA expression in human SK-N-SH cells at EC10 by qPCR method relative to beta-actin2017Bioorganic & medicinal chemistry, 01-15, Volume: 25, Issue:2
Computer design, synthesis, and bioactivity analyses of drugs like fingolimod used in the treatment of multiple sclerosis.
AID1334064Effect on NFKB1 mRNA expression in human SH-SY5Y cells at EC10 by qPCR method relative to beta-actin2017Bioorganic & medicinal chemistry, 01-15, Volume: 25, Issue:2
Computer design, synthesis, and bioactivity analyses of drugs like fingolimod used in the treatment of multiple sclerosis.
AID1735845AUC ratio in orally dosed Sprague-Dawley rat blood assessed as phosphate metabolite to parent compound2019Journal of medicinal chemistry, 03-14, Volume: 62, Issue:5
Identification and Preclinical Pharmacology of ((1 R,3 S)-1-Amino-3-(( S)-6-(2-methoxyphenethyl)-5,6,7,8-tetrahydronaphthalen-2-yl)cyclopentyl)methanol (BMS-986166): A Differentiated Sphingosine-1-phosphate Receptor 1 (S1P
AID1334104Effect on TNF mRNA expression in human U118MG cells at EC10 by qPCR method relative to beta-actin2017Bioorganic & medicinal chemistry, 01-15, Volume: 25, Issue:2
Computer design, synthesis, and bioactivity analyses of drugs like fingolimod used in the treatment of multiple sclerosis.
AID1062571Cardiotoxicity in telemetered spontaneously hypertensive rat assessed as change in heart rate at 10 mg/kg, po administered at wake phase measured up to 24 hrs2013Journal of medicinal chemistry, Dec-12, Volume: 56, Issue:23
Novel S1P1 receptor agonists--part 1: From pyrazoles to thiophenes.
AID1334135Effect on ADRB2 mRNA expression in human U118MG cells at EC10 by qPCR method relative to beta-actin2017Bioorganic & medicinal chemistry, 01-15, Volume: 25, Issue:2
Computer design, synthesis, and bioactivity analyses of drugs like fingolimod used in the treatment of multiple sclerosis.
AID1334198Effect on JUN mRNA expression in human SK-N-SH cells at EC10 by qPCR method relative to beta-actin2017Bioorganic & medicinal chemistry, 01-15, Volume: 25, Issue:2
Computer design, synthesis, and bioactivity analyses of drugs like fingolimod used in the treatment of multiple sclerosis.
AID1334191Effect on TNFRSF1A mRNA expression in human SK-N-SH cells at EC10 by qPCR method relative to beta-actin2017Bioorganic & medicinal chemistry, 01-15, Volume: 25, Issue:2
Computer design, synthesis, and bioactivity analyses of drugs like fingolimod used in the treatment of multiple sclerosis.
AID1334165Effect on IL10 mRNA expression in human SK-N-SH cells at EC10 by qPCR method relative to beta-actin2017Bioorganic & medicinal chemistry, 01-15, Volume: 25, Issue:2
Computer design, synthesis, and bioactivity analyses of drugs like fingolimod used in the treatment of multiple sclerosis.
AID473705Induction of mouse SphK2 phosphorylation2010Bioorganic & medicinal chemistry letters, Apr-01, Volume: 20, Issue:7
Stereochemistry-activity relationship of orally active tetralin S1P agonist prodrugs.
AID1334119Effect on VCAM1 mRNA expression in human U118MG cells at EC10 by qPCR method relative to beta-actin2017Bioorganic & medicinal chemistry, 01-15, Volume: 25, Issue:2
Computer design, synthesis, and bioactivity analyses of drugs like fingolimod used in the treatment of multiple sclerosis.
AID1735808Pulmonary toxicity in Lewis rat assessed as elevation of BAL protein level at 3 mg/kg by advia1800 chemistry analyzer2019Journal of medicinal chemistry, 03-14, Volume: 62, Issue:5
Identification and Preclinical Pharmacology of ((1 R,3 S)-1-Amino-3-(( S)-6-(2-methoxyphenethyl)-5,6,7,8-tetrahydronaphthalen-2-yl)cyclopentyl)methanol (BMS-986166): A Differentiated Sphingosine-1-phosphate Receptor 1 (S1P
AID1370503Agonist activity at human S1P5 receptor expressed in CHO cells assessed as increase in calcium flux by aequorin-derived luminescence assay2018Bioorganic & medicinal chemistry letters, 02-01, Volume: 28, Issue:3
Spiro-1-benzofuranpiperidinylalkanoic acids as a novel and selective sphingosine S1P
AID1334166Effect on IL1B mRNA expression in human SK-N-SH cells at EC10 by qPCR method relative to beta-actin2017Bioorganic & medicinal chemistry, 01-15, Volume: 25, Issue:2
Computer design, synthesis, and bioactivity analyses of drugs like fingolimod used in the treatment of multiple sclerosis.
AID1901438Induction of lymphopenia in rat assessed as reduction in blood lymphocyte count at 1 mg/kg, po measured after 6 hrs2022Journal of medicinal chemistry, 02-24, Volume: 65, Issue:4
Discovery of Novel Sphingosine-1-Phosphate-1 Receptor Agonists for the Treatment of Multiple Sclerosis.
AID1054254Agonist activity at S1P3 receptor (unknown origin)2013Bioorganic & medicinal chemistry letters, Dec-01, Volume: 23, Issue:23
Modulators of the Sphingosine 1-phosphate receptor 1.
AID1334162Effect on CSF1 mRNA expression in human SK-N-SH cells at EC10 by qPCR method relative to beta-actin2017Bioorganic & medicinal chemistry, 01-15, Volume: 25, Issue:2
Computer design, synthesis, and bioactivity analyses of drugs like fingolimod used in the treatment of multiple sclerosis.
AID1334138Effect on GNAS mRNA expression in human U118MG cells at EC10 by qPCR method relative to beta-actin2017Bioorganic & medicinal chemistry, 01-15, Volume: 25, Issue:2
Computer design, synthesis, and bioactivity analyses of drugs like fingolimod used in the treatment of multiple sclerosis.
AID1334019Effect on PTGDR mRNA expression in human SH-SY5Y cells at EC10 by qPCR method relative to beta-actin2017Bioorganic & medicinal chemistry, 01-15, Volume: 25, Issue:2
Computer design, synthesis, and bioactivity analyses of drugs like fingolimod used in the treatment of multiple sclerosis.
AID1713369Inhibition of mouse liver microsomal S1PL using S1P as substrate incubated for 20 mins by ESI-LC/MS analysis2016European journal of medicinal chemistry, Nov-10, Volume: 123Studies on the inhibition of sphingosine-1-phosphate lyase by stabilized reaction intermediates and stereodefined azido phosphates.
AID1185985AUC (0 to t) in Sprague-Dawley rat at 3 mg/kg, po2014European journal of medicinal chemistry, Oct-06, Volume: 85Discovery of oxazole and triazole derivatives as potent and selective S1P(1) agonists through pharmacophore-guided design.
AID1370504Agonist activity at human S1P1 receptor expressed in CHO cells assessed as increase in calcium flux by aequorin-derived luminescence assay2018Bioorganic & medicinal chemistry letters, 02-01, Volume: 28, Issue:3
Spiro-1-benzofuranpiperidinylalkanoic acids as a novel and selective sphingosine S1P
AID1334128Effect on HIF1A mRNA expression in human U118MG cells at EC10 by qPCR method relative to beta-actin2017Bioorganic & medicinal chemistry, 01-15, Volume: 25, Issue:2
Computer design, synthesis, and bioactivity analyses of drugs like fingolimod used in the treatment of multiple sclerosis.
AID1334136Effect on COL1A1 mRNA expression in human U118MG cells at EC10 by qPCR method relative to beta-actin2017Bioorganic & medicinal chemistry, 01-15, Volume: 25, Issue:2
Computer design, synthesis, and bioactivity analyses of drugs like fingolimod used in the treatment of multiple sclerosis.
AID1334223Effect on GRM7 mRNA expression in human SK-N-SH cells at EC10 by qPCR method relative to beta-actin2017Bioorganic & medicinal chemistry, 01-15, Volume: 25, Issue:2
Computer design, synthesis, and bioactivity analyses of drugs like fingolimod used in the treatment of multiple sclerosis.
AID1896040Inhibition of S1PR1 (unknown origin)2021Journal of medicinal chemistry, 12-23, Volume: 64, Issue:24
The Repertoire of Small-Molecule PET Probes for Neuroinflammation Imaging: Challenges and Opportunities beyond TSPO.
AID1673006Immunosuppressive activity in po dosed PLP (139 to 151 residues)-induced experimental autoimmune encephalomyelitis mouse model assessed as incidence of disease administered twice starting from immunization relative to control2019Bioorganic & medicinal chemistry letters, 07-15, Volume: 29, Issue:14
Discovery of novel quinoline sulphonamide derivatives as potent, selective and orally active RORγ inverse agonists.
AID1334130Effect on MYC mRNA expression in human U118MG cells at EC10 by qPCR method relative to beta-actin2017Bioorganic & medicinal chemistry, 01-15, Volume: 25, Issue:2
Computer design, synthesis, and bioactivity analyses of drugs like fingolimod used in the treatment of multiple sclerosis.
AID671363Immunosuppressant activity in autoimmune encephalomyelitis C57B1/6 mouse model assessed as reduction in disease score at 1 mg/kg, po qd administered on day 3 post challenge2012Bioorganic & medicinal chemistry letters, Jul-01, Volume: 22, Issue:13
Fused tricyclic indoles as S1P₁ agonists with robust efficacy in animal models of autoimmune disease.
AID1334050Effect on VCAM1 mRNA expression in human SH-SY5Y cells at EC10 by qPCR method relative to beta-actin2017Bioorganic & medicinal chemistry, 01-15, Volume: 25, Issue:2
Computer design, synthesis, and bioactivity analyses of drugs like fingolimod used in the treatment of multiple sclerosis.
AID1062582Cardiotoxicity in telemetered spontaneously hypertensive rat assessed as increase in mean arterial pressure at 1 to 30 mg/kg, po administered at wake phase measured up to 24 hrs2013Journal of medicinal chemistry, Dec-12, Volume: 56, Issue:23
Novel S1P1 receptor agonists--part 1: From pyrazoles to thiophenes.
AID1370506Aqueous kinetic solubility of the compound by turbidimetric method2018Bioorganic & medicinal chemistry letters, 02-01, Volume: 28, Issue:3
Spiro-1-benzofuranpiperidinylalkanoic acids as a novel and selective sphingosine S1P
AID1062168Prodrug conversion in C57BL/6 mouse assessed as formation of phosphorylated compound at 10 mg/kg, po at 6 hrs post-dose2013ACS medicinal chemistry letters, Oct-10, Volume: 4, Issue:10
Discovery of Clinical Candidate GSK1842799 As a Selective S1P1 Receptor Agonist (Prodrug) for Multiple Sclerosis.
AID1370507Intrinsic clearance in human microsomes assessed per mg protein2018Bioorganic & medicinal chemistry letters, 02-01, Volume: 28, Issue:3
Spiro-1-benzofuranpiperidinylalkanoic acids as a novel and selective sphingosine S1P
AID1271836Agonist activity at human S1P3 receptor expressed in EDG3-bla U2OS cells incubated for 18 hrs prior to GenBlazer substrate addition by beta-arrestin recruitment assay2016Bioorganic & medicinal chemistry letters, Jan-15, Volume: 26, Issue:2
Late-stage optimization of a tercyclic class of S1P3-sparing, S1P1 receptor agonists.
AID1334155Effect on DRD2 mRNA expression in human U118MG cells at EC10 by qPCR method relative to beta-actin2017Bioorganic & medicinal chemistry, 01-15, Volume: 25, Issue:2
Computer design, synthesis, and bioactivity analyses of drugs like fingolimod used in the treatment of multiple sclerosis.
AID1280931Lymphopenia activity in Lewis rat at 1 mg/kg, po measured after 2 to 4 hrs2016Journal of medicinal chemistry, Feb-11, Volume: 59, Issue:3
Discovery of Tetrahydropyrazolopyridine as Sphingosine 1-Phosphate Receptor 3 (S1P3)-Sparing S1P1 Agonists Active at Low Oral Doses.
AID1334184Effect on ICAM1 mRNA expression in human SK-N-SH cells at EC10 by qPCR method relative to beta-actin2017Bioorganic & medicinal chemistry, 01-15, Volume: 25, Issue:2
Computer design, synthesis, and bioactivity analyses of drugs like fingolimod used in the treatment of multiple sclerosis.
AID1334097Effect on CCL3 mRNA expression in human U118MG cells at EC10 by qPCR method relative to beta-actin2017Bioorganic & medicinal chemistry, 01-15, Volume: 25, Issue:2
Computer design, synthesis, and bioactivity analyses of drugs like fingolimod used in the treatment of multiple sclerosis.
AID588213Literature-mined compound from Fourches et al multi-species drug-induced liver injury (DILI) dataset, effect in non-rodents2010Chemical research in toxicology, Jan, Volume: 23, Issue:1
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
AID1334117Effect on ICAM1 mRNA expression in human U118MG cells at EC10 by qPCR method relative to beta-actin2017Bioorganic & medicinal chemistry, 01-15, Volume: 25, Issue:2
Computer design, synthesis, and bioactivity analyses of drugs like fingolimod used in the treatment of multiple sclerosis.
AID1422495Cytotoxicity against mouse FL5.12 cells assessed as vacuole formation at 10 uM after 3 hrs by fluorescence microscopic analysis2018European journal of medicinal chemistry, Nov-05, Volume: 159In search of constrained FTY720 and phytosphingosine analogs as dual acting anticancer agents targeting metabolic and epigenetic pathways.
AID1334148Effect on AKT1 mRNA expression in human U118MG cells at EC10 by qPCR method relative to beta-actin2017Bioorganic & medicinal chemistry, 01-15, Volume: 25, Issue:2
Computer design, synthesis, and bioactivity analyses of drugs like fingolimod used in the treatment of multiple sclerosis.
AID1334113Effect on BCL2 mRNA expression in human U118MG cells at EC10 by qPCR method relative to beta-actin2017Bioorganic & medicinal chemistry, 01-15, Volume: 25, Issue:2
Computer design, synthesis, and bioactivity analyses of drugs like fingolimod used in the treatment of multiple sclerosis.
AID1179541Half life in Lewis rat at 1 mg/kg, po2014Bioorganic & medicinal chemistry, Aug-01, Volume: 22, Issue:15
Synthesis and SAR studies of benzyl ether derivatives as potent orally active S1P₁ agonists.
AID1890680Anti-inflammatory activity in MOG (35 to 55 residues)-induced experimental autoimmune encephalomyelitis mouse model assessed as reversal of clinical scores at 1 mg/kg, INH administered once daily for 25 days2022Bioorganic & medicinal chemistry letters, 05-15, Volume: 64Design, synthesis, and biological evaluation of polyphenol derivatives as DYRK1A inhibitors. The discovery of a potentially promising treatment for Multiple Sclerosis.
AID1334197Effect on HIF1 mRNA expression in human SK-N-SH cells at EC10 by qPCR method relative to beta-actin2017Bioorganic & medicinal chemistry, 01-15, Volume: 25, Issue:2
Computer design, synthesis, and bioactivity analyses of drugs like fingolimod used in the treatment of multiple sclerosis.
AID1334075Effect on TSHR mRNA expression in human SH-SY5Y cells at EC10 by qPCR method relative to beta-actin2017Bioorganic & medicinal chemistry, 01-15, Volume: 25, Issue:2
Computer design, synthesis, and bioactivity analyses of drugs like fingolimod used in the treatment of multiple sclerosis.
AID1730797AUC ratio in orally dosed human blood assessed as phosphate metabolite to parent compound2021Journal of medicinal chemistry, 02-11, Volume: 64, Issue:3
Bicyclic Ligand-Biased Agonists of S1P
AID1334219Effect on CFLAR mRNA expression in human SK-N-SH cells at EC10 by qPCR method relative to beta-actin2017Bioorganic & medicinal chemistry, 01-15, Volume: 25, Issue:2
Computer design, synthesis, and bioactivity analyses of drugs like fingolimod used in the treatment of multiple sclerosis.
AID1300080Induction of colon length shortening in SCID mouse with CD45RBhiCD4+ T-cell transfer-induced colitis model of inflammatory bowel disease at 1 mg/kg, po dosed daily for 5 weeeks2016ACS medicinal chemistry letters, Mar-10, Volume: 7, Issue:3
Identification and Preclinical Pharmacology of BMS-986104: A Differentiated S1P1 Receptor Modulator in Clinical Trials.
AID1626353Half life in human administered as single dose2016Journal of medicinal chemistry, 07-14, Volume: 59, Issue:13
Discovery and Structure-Activity Relationship (SAR) of a Series of Ethanolamine-Based Direct-Acting Agonists of Sphingosine-1-phosphate (S1P1).
AID777393Cytotoxicity against human PC3 cells after 72 hrs by vital dye exclusion/flow cytometric analysis2013ACS medicinal chemistry letters, Oct-10, Volume: 4, Issue:10
Design, Synthesis, and Anti-leukemic Activity of Stereochemically Defined Constrained Analogs of FTY720 (Gilenya).
AID1334096Effect on CCL2 mRNA expression in human U118MG cells at EC10 by qPCR method relative to beta-actin2017Bioorganic & medicinal chemistry, 01-15, Volume: 25, Issue:2
Computer design, synthesis, and bioactivity analyses of drugs like fingolimod used in the treatment of multiple sclerosis.
AID1054255Agonist activity at S1P1 receptor (unknown origin)2013Bioorganic & medicinal chemistry letters, Dec-01, Volume: 23, Issue:23
Modulators of the Sphingosine 1-phosphate receptor 1.
AID1334069Effect on COL1A1 mRNA expression in human SH-SY5Y cells at EC10 by qPCR method relative to beta-actin2017Bioorganic & medicinal chemistry, 01-15, Volume: 25, Issue:2
Computer design, synthesis, and bioactivity analyses of drugs like fingolimod used in the treatment of multiple sclerosis.
AID1257235Immunosuppressive activity in mouse assessed as induction of lymphopenia at 1.25 mg/kg, ip after 24 hrs by flow cytometry2015Bioorganic & medicinal chemistry letters, Nov-15, Volume: 25, Issue:22
New fluorinated agonists for targeting the sphingosin-1-phosphate receptor 1 (S1P(1)).
AID1054252Agonist activity at S1P5 receptor (unknown origin)2013Bioorganic & medicinal chemistry letters, Dec-01, Volume: 23, Issue:23
Modulators of the Sphingosine 1-phosphate receptor 1.
AID1334205Effect on COL1A1 mRNA expression in human SK-N-SH cells at EC10 by qPCR method relative to beta-actin2017Bioorganic & medicinal chemistry, 01-15, Volume: 25, Issue:2
Computer design, synthesis, and bioactivity analyses of drugs like fingolimod used in the treatment of multiple sclerosis.
AID1917907Anticancer activity against human SH-SY5Y cells assessed as reduction in cell viability incubated for 48 hrs by resazurin dye based fluorescence assay2022Bioorganic & medicinal chemistry, 11-01, Volume: 73Multiple approaches to repurposing drugs for neuroblastoma.
AID777390Cytotoxicity against BCR-ABL fusion protein 190 expressing mouse bone marrow cells after 72 hrs by vital dye exclusion/flow cytometric analysis2013ACS medicinal chemistry letters, Oct-10, Volume: 4, Issue:10
Design, Synthesis, and Anti-leukemic Activity of Stereochemically Defined Constrained Analogs of FTY720 (Gilenya).
AID1334043Effect on BCL2 mRNA expression in human SH-SY5Y cells at EC10 by qPCR method relative to beta-actin2017Bioorganic & medicinal chemistry, 01-15, Volume: 25, Issue:2
Computer design, synthesis, and bioactivity analyses of drugs like fingolimod used in the treatment of multiple sclerosis.
AID1152734Inhibition of S1PL (unknown origin)2014Journal of medicinal chemistry, Jun-26, Volume: 57, Issue:12
Orally active 7-substituted (4-benzylphthalazin-1-yl)-2-methylpiperazin-1-yl]nicotinonitriles as active-site inhibitors of sphingosine 1-phosphate lyase for the treatment of multiple sclerosis.
AID258414Rate of phosphorylation by recombinant human SPHK12006Bioorganic & medicinal chemistry letters, Jan-01, Volume: 16, Issue:1
NBD-labeled derivatives of the immunomodulatory drug FTY720 as tools for metabolism and mode of action studies.
AID1627820Cytotoxicity against mouse FL5.12A cells after 48 hrs by DAPI staining-based flow cytometric analysis2016Bioorganic & medicinal chemistry, 09-15, Volume: 24, Issue:18
Effects of stereochemistry, saturation, and hydrocarbon chain length on the ability of synthetic constrained azacyclic sphingolipids to trigger nutrient transporter down-regulation, vacuolation, and cell death.
AID1334031Effect on IL1B mRNA expression in human SH-SY5Y cells at EC10 by qPCR method relative to beta-actin2017Bioorganic & medicinal chemistry, 01-15, Volume: 25, Issue:2
Computer design, synthesis, and bioactivity analyses of drugs like fingolimod used in the treatment of multiple sclerosis.
AID1179547Cmax in rat at 1 mg/kg, po2014Bioorganic & medicinal chemistry, Aug-01, Volume: 22, Issue:15
Synthesis and SAR studies of benzyl ether derivatives as potent orally active S1P₁ agonists.
AID1422500Cytotoxicity against mouse FL5.12 cells assessed as vacuole formation at 2.5 uM after 3 hrs by fluorescence microscopic analysis2018European journal of medicinal chemistry, Nov-05, Volume: 159In search of constrained FTY720 and phytosphingosine analogs as dual acting anticancer agents targeting metabolic and epigenetic pathways.
AID1334209Effect on OPRD1 mRNA expression in human SK-N-SH cells at EC10 by qPCR method relative to beta-actin2017Bioorganic & medicinal chemistry, 01-15, Volume: 25, Issue:2
Computer design, synthesis, and bioactivity analyses of drugs like fingolimod used in the treatment of multiple sclerosis.
AID1334187Effect on MMP9 mRNA expression in human SK-N-SH cells at EC10 by qPCR method relative to beta-actin2017Bioorganic & medicinal chemistry, 01-15, Volume: 25, Issue:2
Computer design, synthesis, and bioactivity analyses of drugs like fingolimod used in the treatment of multiple sclerosis.
AID1334055Effect on TNFRSF1A mRNA expression in human SH-SY5Y cells at EC10 by qPCR method relative to beta-actin2017Bioorganic & medicinal chemistry, 01-15, Volume: 25, Issue:2
Computer design, synthesis, and bioactivity analyses of drugs like fingolimod used in the treatment of multiple sclerosis.
AID1334049Effect on ITGB2 mRNA expression in human SH-SY5Y cells at EC10 by qPCR method relative to beta-actin2017Bioorganic & medicinal chemistry, 01-15, Volume: 25, Issue:2
Computer design, synthesis, and bioactivity analyses of drugs like fingolimod used in the treatment of multiple sclerosis.
AID357390Reversal of inhibition of mitochondrial function in human Jurkat cells after 18 hrs in presence of Z-VAD-fmk2007The Journal of biological chemistry, May-25, Volume: 282, Issue:21
Essential requirement for sphingosine kinase 2 in a sphingolipid apoptosis pathway activated by FTY720 analogues.
AID1334154Effect on AGTR2 mRNA expression in human U118MG cells at EC10 by qPCR method relative to beta-actin2017Bioorganic & medicinal chemistry, 01-15, Volume: 25, Issue:2
Computer design, synthesis, and bioactivity analyses of drugs like fingolimod used in the treatment of multiple sclerosis.
AID706333Increase in allograft survival in stringent Dark Agouti to Lewis rat heterotopic vascular heart allotransplantation model assessed as allograft mean survival time at 0.1 mg/kg, po qd co-treated with 0.3 mg/kg, qd everolimus2012Journal of medicinal chemistry, Nov-26, Volume: 55, Issue:22
An oral sphingosine 1-phosphate receptor 1 (S1P(1)) antagonist prodrug with efficacy in vivo: discovery, synthesis, and evaluation.
AID1334200Effect on NFKB1 mRNA expression in human SK-N-SH cells at EC10 by qPCR method relative to beta-actin2017Bioorganic & medicinal chemistry, 01-15, Volume: 25, Issue:2
Computer design, synthesis, and bioactivity analyses of drugs like fingolimod used in the treatment of multiple sclerosis.
AID1334164Effect on IFNG mRNA expression in human SK-N-SH cells at EC10 by qPCR method relative to beta-actin2017Bioorganic & medicinal chemistry, 01-15, Volume: 25, Issue:2
Computer design, synthesis, and bioactivity analyses of drugs like fingolimod used in the treatment of multiple sclerosis.
AID1334167Effect on IL6 mRNA expression in human SK-N-SH cells at EC10 by qPCR method relative to beta-actin2017Bioorganic & medicinal chemistry, 01-15, Volume: 25, Issue:2
Computer design, synthesis, and bioactivity analyses of drugs like fingolimod used in the treatment of multiple sclerosis.
AID1334016Agonist activity at sphingosine-1-phosphate receptor human SK-N-SH cells assessed as increase in cAMP level at EC10 by direct immunoassay2017Bioorganic & medicinal chemistry, 01-15, Volume: 25, Issue:2
Computer design, synthesis, and bioactivity analyses of drugs like fingolimod used in the treatment of multiple sclerosis.
AID671380Toxicity in telemeterized Charles-River Sprague-Dawley rat assessed as reduction in heart rate at 3 mg/kg, po measured over 20 hrs2012Bioorganic & medicinal chemistry letters, Jul-01, Volume: 22, Issue:13
Fused tricyclic indoles as S1P₁ agonists with robust efficacy in animal models of autoimmune disease.
AID1422493Downregulation of CD98 expression in mouse FL5.12 cells at 40 uM after 3 hrs by DAPI staining-based FACS analysis relative to control2018European journal of medicinal chemistry, Nov-05, Volume: 159In search of constrained FTY720 and phytosphingosine analogs as dual acting anticancer agents targeting metabolic and epigenetic pathways.
AID1422494Cytotoxicity against mouse FL5.12 cells assessed as vacuole formation at 40 uM after 3 hrs by fluorescence microscopic analysis2018European journal of medicinal chemistry, Nov-05, Volume: 159In search of constrained FTY720 and phytosphingosine analogs as dual acting anticancer agents targeting metabolic and epigenetic pathways.
AID1300056Reduction in lymphocyte level in BALB/c mouse assessed as blood lymphocyte level at 0.5 mg/kg, po after 24 hrs by hematology analysis (Rvb = 5.13 to 8.02 10'3/mm3)2016ACS medicinal chemistry letters, Mar-10, Volume: 7, Issue:3
Identification and Preclinical Pharmacology of BMS-986104: A Differentiated S1P1 Receptor Modulator in Clinical Trials.
AID1054253Agonist activity at S1P4 receptor (unknown origin)2013Bioorganic & medicinal chemistry letters, Dec-01, Volume: 23, Issue:23
Modulators of the Sphingosine 1-phosphate receptor 1.
AID1185987Apparent volume of distribution in steady state in Sprague-Dawley rat at 3 mg/kg, po2014European journal of medicinal chemistry, Oct-06, Volume: 85Discovery of oxazole and triazole derivatives as potent and selective S1P(1) agonists through pharmacophore-guided design.
AID362335Antiangiogenic activity in chick embryo chorioallantoic membrane assessed as number of eggs showing 3 mm avascular zone at 100 ug2008Bioorganic & medicinal chemistry, Aug-15, Volume: 16, Issue:16
TX-2152: a conformationally rigid and electron-rich diyne analogue of FTY720 with in vivo antiangiogenic activity.
AID1334226Effect on DRD2 mRNA expression in human SK-N-SH cells at EC10 by qPCR method relative to beta-actin2017Bioorganic & medicinal chemistry, 01-15, Volume: 25, Issue:2
Computer design, synthesis, and bioactivity analyses of drugs like fingolimod used in the treatment of multiple sclerosis.
AID596411Antiproliferative activity against human SK-BR-3 cells assessed as growth inhibition after 78 hrs by WST-1 assay2011Journal of natural products, Apr-25, Volume: 74, Issue:4
Fingolimod (FTY720): a recently approved multiple sclerosis drug based on a fungal secondary metabolite.
AID596406Immunosuppressive activity in F344 rat lateral thorax transplanted with dorsal skin of LEW rat assessed as increase of skin graft survival time at 1 mg/kg, ip2011Journal of natural products, Apr-25, Volume: 74, Issue:4
Fingolimod (FTY720): a recently approved multiple sclerosis drug based on a fungal secondary metabolite.
AID1334074Effect on S1PR1 mRNA expression in human SH-SY5Y cells at EC10 by qPCR method relative to beta-actin2017Bioorganic & medicinal chemistry, 01-15, Volume: 25, Issue:2
Computer design, synthesis, and bioactivity analyses of drugs like fingolimod used in the treatment of multiple sclerosis.
AID1334150Effect on PIK3CG mRNA expression in human U118MG cells at EC10 by qPCR method relative to beta-actin2017Bioorganic & medicinal chemistry, 01-15, Volume: 25, Issue:2
Computer design, synthesis, and bioactivity analyses of drugs like fingolimod used in the treatment of multiple sclerosis.
AID1334185Effect on ITGB2 mRNA expression in human SK-N-SH cells at EC10 by qPCR method relative to beta-actin2017Bioorganic & medicinal chemistry, 01-15, Volume: 25, Issue:2
Computer design, synthesis, and bioactivity analyses of drugs like fingolimod used in the treatment of multiple sclerosis.
AID1334044Effect on FASLG mRNA expression in human SH-SY5Y cells at EC10 by qPCR method relative to beta-actin2017Bioorganic & medicinal chemistry, 01-15, Volume: 25, Issue:2
Computer design, synthesis, and bioactivity analyses of drugs like fingolimod used in the treatment of multiple sclerosis.
AID1334203Effect on ADORA2A mRNA expression in human SK-N-SH cells at EC10 by qPCR method relative to beta-actin2017Bioorganic & medicinal chemistry, 01-15, Volume: 25, Issue:2
Computer design, synthesis, and bioactivity analyses of drugs like fingolimod used in the treatment of multiple sclerosis.
AID371965Induction of lymphopenia in 129/SvEvBrd x C57BL/6 hybrid mouse assessed as reduction in lymphocyte level from peripheral circulation at 10 mg/kg by complete blood count analysis2009Journal of medicinal chemistry, Jul-09, Volume: 52, Issue:13
Inhibition of sphingosine-1-phosphate lyase for the treatment of autoimmune disorders.
AID1334206Effect on CYP19A1 mRNA expression in human SK-N-SH cells at EC10 by qPCR method relative to beta-actin2017Bioorganic & medicinal chemistry, 01-15, Volume: 25, Issue:2
Computer design, synthesis, and bioactivity analyses of drugs like fingolimod used in the treatment of multiple sclerosis.
AID1062170Prodrug conversion assessed as mouse SphK2-mediated formation of phosphorylated compound2013ACS medicinal chemistry letters, Oct-10, Volume: 4, Issue:10
Discovery of Clinical Candidate GSK1842799 As a Selective S1P1 Receptor Agonist (Prodrug) for Multiple Sclerosis.
AID1300086Reduction in CD11b gene expression in SCID mouse with CD45RBhiCD4+ T-cell transfer-induced colitis model of inflammatory bowel disease at 5 mg/kg, po dosed every other day for 5 weeks by RT-PCR method2016ACS medicinal chemistry letters, Mar-10, Volume: 7, Issue:3
Identification and Preclinical Pharmacology of BMS-986104: A Differentiated S1P1 Receptor Modulator in Clinical Trials.
AID268318Lowering of peripheral blood lymphocyte in Lewis rat at 1 mg/kg, po2006Bioorganic & medicinal chemistry letters, Jul-15, Volume: 16, Issue:14
Discovery of 3-arylpropionic acids as potent agonists of sphingosine-1-phosphate receptor-1 (S1P1) with high selectivity against all other known S1P receptor subtypes.
AID1179539Induction of lymphopenia in Lewis rat assessed as reduction in lymphocyte numbers at 0.1 mg/kg, po after 4 hrs by automatic hemacytometry relative to untreated control2014Bioorganic & medicinal chemistry, Aug-01, Volume: 22, Issue:15
Synthesis and SAR studies of benzyl ether derivatives as potent orally active S1P₁ agonists.
AID1257233Immunosuppressive activity in mouse assessed as reduction of CD8+ level in peripheral blood assessed per 10'6 cells at 1.25 mg/kg, ip after 24 hrs by flow cytometry (Rvb = 0.48 +/- 0.05 ml)2015Bioorganic & medicinal chemistry letters, Nov-15, Volume: 25, Issue:22
New fluorinated agonists for targeting the sphingosin-1-phosphate receptor 1 (S1P(1)).
AID1846064Antitumor activity against human D425 Med cells assessed as reduction in cell viability incubated for 24 hrs by Alamar blue assay2021European journal of medicinal chemistry, Apr-05, Volume: 215Medulloblastoma drugs in development: Current leads, trials and drawbacks.
AID1334033Effect on TNF mRNA expression in human SH-SY5Y cells at EC10 by qPCR method relative to beta-actin2017Bioorganic & medicinal chemistry, 01-15, Volume: 25, Issue:2
Computer design, synthesis, and bioactivity analyses of drugs like fingolimod used in the treatment of multiple sclerosis.
AID1185983Tmax in Sprague-Dawley rat at 3 mg/kg, po2014European journal of medicinal chemistry, Oct-06, Volume: 85Discovery of oxazole and triazole derivatives as potent and selective S1P(1) agonists through pharmacophore-guided design.
AID305218Effect on rate of phosphorylation of human recombinant SPHK1 expressed in HEK293 cells2007Bioorganic & medicinal chemistry letters, Jan-15, Volume: 17, Issue:2
Constrained azacyclic analogues of the immunomodulatory agent FTY720 as molecular probes for sphingosine 1-phosphate receptors.
AID1334211Effect on TSHR mRNA expression in human SK-N-SH cells at EC10 by qPCR method relative to beta-actin2017Bioorganic & medicinal chemistry, 01-15, Volume: 25, Issue:2
Computer design, synthesis, and bioactivity analyses of drugs like fingolimod used in the treatment of multiple sclerosis.
AID777392Cytotoxicity against human DU145 cells after 72 hrs by vital dye exclusion/flow cytometric analysis2013ACS medicinal chemistry letters, Oct-10, Volume: 4, Issue:10
Design, Synthesis, and Anti-leukemic Activity of Stereochemically Defined Constrained Analogs of FTY720 (Gilenya).
AID1334161Effect on CCL3 mRNA expression in human SK-N-SH cells at EC10 by qPCR method relative to beta-actin2017Bioorganic & medicinal chemistry, 01-15, Volume: 25, Issue:2
Computer design, synthesis, and bioactivity analyses of drugs like fingolimod used in the treatment of multiple sclerosis.
AID1334182Effect on RAF1 mRNA expression in human SK-N-SH cells at EC10 by qPCR method relative to beta-actin2017Bioorganic & medicinal chemistry, 01-15, Volume: 25, Issue:2
Computer design, synthesis, and bioactivity analyses of drugs like fingolimod used in the treatment of multiple sclerosis.
AID1062146Selectivity ratio for human Sphk1 to human Sphk22013ACS medicinal chemistry letters, Oct-10, Volume: 4, Issue:10
Discovery of Clinical Candidate GSK1842799 As a Selective S1P1 Receptor Agonist (Prodrug) for Multiple Sclerosis.
AID1334207Effect on GNAS mRNA expression in human SK-N-SH cells at EC10 by qPCR method relative to beta-actin2017Bioorganic & medicinal chemistry, 01-15, Volume: 25, Issue:2
Computer design, synthesis, and bioactivity analyses of drugs like fingolimod used in the treatment of multiple sclerosis.
AID596415Antitumor activity against human MGC803 cells xenografted in nude mouse assessed as inhibition of tumor growth at 10 mg/kg for 20 days2011Journal of natural products, Apr-25, Volume: 74, Issue:4
Fingolimod (FTY720): a recently approved multiple sclerosis drug based on a fungal secondary metabolite.
AID473707Immunosuppressive activity in mouse assessed as induction of lymphopenia2010Bioorganic & medicinal chemistry letters, Apr-01, Volume: 20, Issue:7
Stereochemistry-activity relationship of orally active tetralin S1P agonist prodrugs.
AID1334067Effect on ADORA2A mRNA expression in human SH-SY5Y cells at EC10 by qPCR method relative to beta-actin2017Bioorganic & medicinal chemistry, 01-15, Volume: 25, Issue:2
Computer design, synthesis, and bioactivity analyses of drugs like fingolimod used in the treatment of multiple sclerosis.
AID596408Inhibition of serine palmitoyltransferase in mouse spleen cells2011Journal of natural products, Apr-25, Volume: 74, Issue:4
Fingolimod (FTY720): a recently approved multiple sclerosis drug based on a fungal secondary metabolite.
AID1334091Effect on DRD2 mRNA expression in human SH-SY5Y cells at EC10 by qPCR method relative to beta-actin2017Bioorganic & medicinal chemistry, 01-15, Volume: 25, Issue:2
Computer design, synthesis, and bioactivity analyses of drugs like fingolimod used in the treatment of multiple sclerosis.
AID672978Antiinflammatory activity in C57BL/6 mouse EAE model assessed as decrease in clinical symptoms at 1 mg/kg, po administered qd after 10 days post immunization2012Journal of medicinal chemistry, May-10, Volume: 55, Issue:9
Discovery of novel 1,2,4-thiadiazole derivatives as potent, orally active agonists of sphingosine 1-phosphate receptor subtype 1 (S1P(1)).
AID1334088Effect on GRM7 mRNA expression in human SH-SY5Y cells at EC10 by qPCR method relative to beta-actin2017Bioorganic & medicinal chemistry, 01-15, Volume: 25, Issue:2
Computer design, synthesis, and bioactivity analyses of drugs like fingolimod used in the treatment of multiple sclerosis.
AID1474288Toxicity in human assessed as reduction in heart rate measured every day for 9 days2017Journal of medicinal chemistry, 07-13, Volume: 60, Issue:13
Modulators of Sphingosine-1-phosphate Pathway Biology: Recent Advances of Sphingosine-1-phosphate Receptor 1 (S1P
AID1334142Effect on TSHR mRNA expression in human U118MG cells at EC10 by qPCR method relative to beta-actin2017Bioorganic & medicinal chemistry, 01-15, Volume: 25, Issue:2
Computer design, synthesis, and bioactivity analyses of drugs like fingolimod used in the treatment of multiple sclerosis.
AID1179540Immunosuppressive activity in Lewis rat injected with WKAH/Hkm rat spleen cells assessed as inhibition of host versus graft reaction by measuring popliteal lymph nodes weight dosed orally at 5 mL/kg once daily for 4 successive days starting on day of sple2014Bioorganic & medicinal chemistry, Aug-01, Volume: 22, Issue:15
Synthesis and SAR studies of benzyl ether derivatives as potent orally active S1P₁ agonists.
AID258415Rate of phosphorylation by recombinant human SPHK2 using2006Bioorganic & medicinal chemistry letters, Jan-01, Volume: 16, Issue:1
NBD-labeled derivatives of the immunomodulatory drug FTY720 as tools for metabolism and mode of action studies.
AID1152735Inhibition of human recombinant S1PL (62 to 568) expressed in Sf9 insect cells using S1P as substrate after 1 hr2014Journal of medicinal chemistry, Jun-26, Volume: 57, Issue:12
Orally active 7-substituted (4-benzylphthalazin-1-yl)-2-methylpiperazin-1-yl]nicotinonitriles as active-site inhibitors of sphingosine 1-phosphate lyase for the treatment of multiple sclerosis.
AID362336Antiangiogenic activity in chick embryo chorioallantoic membrane assessed as number of eggs showing 3 mm avascular zone at 10 ug2008Bioorganic & medicinal chemistry, Aug-15, Volume: 16, Issue:16
TX-2152: a conformationally rigid and electron-rich diyne analogue of FTY720 with in vivo antiangiogenic activity.
AID240248Agonism of human S1P-2 receptor expressed in CHO cells, 90-120 min in pH 7.4 using [35S]GTP-gamma-S as radioligand2005Journal of medicinal chemistry, Aug-11, Volume: 48, Issue:16
Novel immunomodulator FTY720 is phosphorylated in rats and humans to form a single stereoisomer. Identification, chemical proof, and biological characterization of the biologically active species and its enantiomer.
AID1334134Effect on ADORA2A mRNA expression in human U118MG cells at EC10 by qPCR method relative to beta-actin2017Bioorganic & medicinal chemistry, 01-15, Volume: 25, Issue:2
Computer design, synthesis, and bioactivity analyses of drugs like fingolimod used in the treatment of multiple sclerosis.
AID1062158Reduction in clinical symptoms in MOG peptide experimental autoimmune encephalitis (EAE) mouse multiple sclerosis disease model at 3 mg/kg, po qd2013ACS medicinal chemistry letters, Oct-10, Volume: 4, Issue:10
Discovery of Clinical Candidate GSK1842799 As a Selective S1P1 Receptor Agonist (Prodrug) for Multiple Sclerosis.
AID1216145Terminal half life in human2011Drug metabolism and disposition: the biological fate of chemicals, Feb, Volume: 39, Issue:2
CYP4F enzymes are responsible for the elimination of fingolimod (FTY720), a novel treatment of relapsing multiple sclerosis.
AID1370508Half life in human microsomes assessed per mg protein2018Bioorganic & medicinal chemistry letters, 02-01, Volume: 28, Issue:3
Spiro-1-benzofuranpiperidinylalkanoic acids as a novel and selective sphingosine S1P
AID1185031Induction of PP2A catalytic subunit activity in rat PC12 cells assessed as phosphate level at 5 uM measured 30 to 120 mins2014ACS medicinal chemistry letters, Jul-10, Volume: 5, Issue:7
Novel FTY720-Based Compounds Stimulate Neurotrophin Expression and Phosphatase Activity in Dopaminergic Cells.
AID1176727Half life in human2014ACS medicinal chemistry letters, Dec-11, Volume: 5, Issue:12
(7-Benzyloxy-2,3-dihydro-1H-pyrrolo[1,2-a]indol-1-yl)acetic Acids as S1P1 Functional Antagonists.
AID1179549Half life in rat at 1 mg/kg, po2014Bioorganic & medicinal chemistry, Aug-01, Volume: 22, Issue:15
Synthesis and SAR studies of benzyl ether derivatives as potent orally active S1P₁ agonists.
AID1334121Effect on EDNRA mRNA expression in human U118MG cells at EC10 by qPCR method relative to beta-actin2017Bioorganic & medicinal chemistry, 01-15, Volume: 25, Issue:2
Computer design, synthesis, and bioactivity analyses of drugs like fingolimod used in the treatment of multiple sclerosis.
AID1334188Effect on CD44 mRNA expression in human SK-N-SH cells at EC10 by qPCR method relative to beta-actin2017Bioorganic & medicinal chemistry, 01-15, Volume: 25, Issue:2
Computer design, synthesis, and bioactivity analyses of drugs like fingolimod used in the treatment of multiple sclerosis.
AID1334070Effect on CYP19A1 mRNA expression in human SH-SY5Y cells at EC10 by qPCR method relative to beta-actin2017Bioorganic & medicinal chemistry, 01-15, Volume: 25, Issue:2
Computer design, synthesis, and bioactivity analyses of drugs like fingolimod used in the treatment of multiple sclerosis.
AID596413Antiproliferative activity against human SW620 cells assessed as growth inhibition after 78 hrs by WST-1 assay2011Journal of natural products, Apr-25, Volume: 74, Issue:4
Fingolimod (FTY720): a recently approved multiple sclerosis drug based on a fungal secondary metabolite.
AID1300091Reduction in OASL2 gene expression in SCID mouse with CD45RBhiCD4+ T-cell transfer-induced colitis model of inflammatory bowel disease at 5 mg/kg, po dosed every other day for 5 weeks by RT-PCR method2016ACS medicinal chemistry letters, Mar-10, Volume: 7, Issue:3
Identification and Preclinical Pharmacology of BMS-986104: A Differentiated S1P1 Receptor Modulator in Clinical Trials.
AID1062169Prodrug conversion assessed as human SphK2-mediated formation of phosphorylated compound2013ACS medicinal chemistry letters, Oct-10, Volume: 4, Issue:10
Discovery of Clinical Candidate GSK1842799 As a Selective S1P1 Receptor Agonist (Prodrug) for Multiple Sclerosis.
AID1334168Effect on TNF mRNA expression in human SK-N-SH cells at EC10 by qPCR method relative to beta-actin2017Bioorganic & medicinal chemistry, 01-15, Volume: 25, Issue:2
Computer design, synthesis, and bioactivity analyses of drugs like fingolimod used in the treatment of multiple sclerosis.
AID1257234Immunosuppressive activity in mouse assessed as reduction of B-cells level in peripheral blood assessed per 10'6 cells at 1.25 mg/kg, ip after 24 hrs by flow cytometry (Rvb = 4.72 +/- 0.53 ml)2015Bioorganic & medicinal chemistry letters, Nov-15, Volume: 25, Issue:22
New fluorinated agonists for targeting the sphingosin-1-phosphate receptor 1 (S1P(1)).
AID642403Agonist activity at human S1P1 receptor expressed in human U2OS cells co-expressing eGFP assessed as receptor internalization into cytoplasm using Hoechst dye staining2012Bioorganic & medicinal chemistry letters, Jan-01, Volume: 22, Issue:1
Quinolinone-based agonists of S1P₁: use of a N-scan SAR strategy to optimize in vitro and in vivo activity.
AID1334048Effect on ICAM1 mRNA expression in human SH-SY5Y cells at EC10 by qPCR method relative to beta-actin2017Bioorganic & medicinal chemistry, 01-15, Volume: 25, Issue:2
Computer design, synthesis, and bioactivity analyses of drugs like fingolimod used in the treatment of multiple sclerosis.
AID1334137Effect on CYP19A1 mRNA expression in human U118MG cells at EC10 by qPCR method relative to beta-actin2017Bioorganic & medicinal chemistry, 01-15, Volume: 25, Issue:2
Computer design, synthesis, and bioactivity analyses of drugs like fingolimod used in the treatment of multiple sclerosis.
AID1334061Effect on HIF1A mRNA expression in human SH-SY5Y cells at EC10 by qPCR method relative to beta-actin2017Bioorganic & medicinal chemistry, 01-15, Volume: 25, Issue:2
Computer design, synthesis, and bioactivity analyses of drugs like fingolimod used in the treatment of multiple sclerosis.
AID1334140Effect on OPRD1 mRNA expression in human U118MG cells at EC10 by qPCR method relative to beta-actin2017Bioorganic & medicinal chemistry, 01-15, Volume: 25, Issue:2
Computer design, synthesis, and bioactivity analyses of drugs like fingolimod used in the treatment of multiple sclerosis.
AID596412Antiproliferative activity against human HCT116 cells assessed as growth inhibition after 78 hrs by WST-1 assay2011Journal of natural products, Apr-25, Volume: 74, Issue:4
Fingolimod (FTY720): a recently approved multiple sclerosis drug based on a fungal secondary metabolite.
AID1334139Effect on NOS2 mRNA expression in human U118MG cells at EC10 by qPCR method relative to beta-actin2017Bioorganic & medicinal chemistry, 01-15, Volume: 25, Issue:2
Computer design, synthesis, and bioactivity analyses of drugs like fingolimod used in the treatment of multiple sclerosis.
AID1334225Effect on AGTR2 mRNA expression in human SK-N-SH cells at EC10 by qPCR method relative to beta-actin2017Bioorganic & medicinal chemistry, 01-15, Volume: 25, Issue:2
Computer design, synthesis, and bioactivity analyses of drugs like fingolimod used in the treatment of multiple sclerosis.
AID1300061Pulmonary toxicity in BALB/c mouse assessed as BAL protein levels at 30 mg/kg, po after 24 by hematology analysis (Rvb = 8.2 to 8.3 mg/dL)2016ACS medicinal chemistry letters, Mar-10, Volume: 7, Issue:3
Identification and Preclinical Pharmacology of BMS-986104: A Differentiated S1P1 Receptor Modulator in Clinical Trials.
AID1735848AUC ratio in orally dosed human blood assessed as phosphate metabolite to parent compound2019Journal of medicinal chemistry, 03-14, Volume: 62, Issue:5
Identification and Preclinical Pharmacology of ((1 R,3 S)-1-Amino-3-(( S)-6-(2-methoxyphenethyl)-5,6,7,8-tetrahydronaphthalen-2-yl)cyclopentyl)methanol (BMS-986166): A Differentiated Sphingosine-1-phosphate Receptor 1 (S1P
AID1730796AUC ratio in orally dosed Beagle dog blood assessed as phosphate metabolite to parent compound2021Journal of medicinal chemistry, 02-11, Volume: 64, Issue:3
Bicyclic Ligand-Biased Agonists of S1P
AID1334196Effect on HDAC1 mRNA expression in human SK-N-SH cells at EC10 by qPCR method relative to beta-actin2017Bioorganic & medicinal chemistry, 01-15, Volume: 25, Issue:2
Computer design, synthesis, and bioactivity analyses of drugs like fingolimod used in the treatment of multiple sclerosis.
AID1334030Effect on IL10 mRNA expression in human SH-SY5Y cells at EC10 by qPCR method relative to beta-actin2017Bioorganic & medicinal chemistry, 01-15, Volume: 25, Issue:2
Computer design, synthesis, and bioactivity analyses of drugs like fingolimod used in the treatment of multiple sclerosis.
AID1334201Effect on STAT3 mRNA expression in human SK-N-SH cells at EC10 by qPCR method relative to beta-actin2017Bioorganic & medicinal chemistry, 01-15, Volume: 25, Issue:2
Computer design, synthesis, and bioactivity analyses of drugs like fingolimod used in the treatment of multiple sclerosis.
AID1334131Effect on NFKB1 mRNA expression in human U118MG cells at EC10 by qPCR method relative to beta-actin2017Bioorganic & medicinal chemistry, 01-15, Volume: 25, Issue:2
Computer design, synthesis, and bioactivity analyses of drugs like fingolimod used in the treatment of multiple sclerosis.
AID1300088Reduction in B220 gene expression in SCID mouse with CD45RBhiCD4+ T-cell transfer-induced colitis model of inflammatory bowel disease at 5 mg/kg, po dosed every other day for 5 weeks by RT-PCR method2016ACS medicinal chemistry letters, Mar-10, Volume: 7, Issue:3
Identification and Preclinical Pharmacology of BMS-986104: A Differentiated S1P1 Receptor Modulator in Clinical Trials.
AID642478Agonist activity at human S1P1 receptor expressed in human U2OS cells co-expressing eGFP assessed as receptor internalization into cytoplasm using Hoechst dye staining relative to 1-(4-(6-benzylbenzofuran-2-yl)-3- fluorobenzyl)azetidine-3-carboxylic acid2012Bioorganic & medicinal chemistry letters, Jan-01, Volume: 22, Issue:1
Quinolinone-based agonists of S1P₁: use of a N-scan SAR strategy to optimize in vitro and in vivo activity.
AID1300085Reduction in IFNgamma gene expression in SCID mouse with CD45RBhiCD4+ T-cell transfer-induced colitis model of inflammatory bowel disease at 5 mg/kg, po dosed every other day for 5 weeks by RT-PCR method2016ACS medicinal chemistry letters, Mar-10, Volume: 7, Issue:3
Identification and Preclinical Pharmacology of BMS-986104: A Differentiated S1P1 Receptor Modulator in Clinical Trials.
AID1179543Drug metabolism in rat plasma assessed as compound phosphorylation at 100 ug/ml at 37 degC after 3 hrs by HPLC method2014Bioorganic & medicinal chemistry, Aug-01, Volume: 22, Issue:15
Synthesis and SAR studies of benzyl ether derivatives as potent orally active S1P₁ agonists.
AID240247Agonism of human S1P-1 receptor expressed in CHO cells, 90-120 min in pH 7.4 using [35S]GTP-gamma-S as radioligand2005Journal of medicinal chemistry, Aug-11, Volume: 48, Issue:16
Novel immunomodulator FTY720 is phosphorylated in rats and humans to form a single stereoisomer. Identification, chemical proof, and biological characterization of the biologically active species and its enantiomer.
AID1054244Half life in human2013Bioorganic & medicinal chemistry letters, Dec-01, Volume: 23, Issue:23
Modulators of the Sphingosine 1-phosphate receptor 1.
AID282267Displacement of [33P]sphingosine 1 phosphate from human S1P1 receptor expressed in CHO cells2004Journal of medicinal chemistry, Dec-30, Volume: 47, Issue:27
A rational utilization of high-throughput screening affords selective, orally bioavailable 1-benzyl-3-carboxyazetidine sphingosine-1-phosphate-1 receptor agonists.
AID1334090Effect on AGTR2 mRNA expression in human SH-SY5Y cells at EC10 by qPCR method relative to beta-actin2017Bioorganic & medicinal chemistry, 01-15, Volume: 25, Issue:2
Computer design, synthesis, and bioactivity analyses of drugs like fingolimod used in the treatment of multiple sclerosis.
AID1185033Induction of PP2A catalytic subunit activity in mouse MN9D cells assessed as phosphate level at 5 uM2014ACS medicinal chemistry letters, Jul-10, Volume: 5, Issue:7
Novel FTY720-Based Compounds Stimulate Neurotrophin Expression and Phosphatase Activity in Dopaminergic Cells.
AID1532420Immunosuppressive activity in po dosed human assessed as decrease in peripheral blood lymphocyte count measured after 21 days of continuous treatment2018Bioorganic & medicinal chemistry letters, 12-15, Volume: 28, Issue:23-24
An update on sphingosine-1-phosphate receptor 1 modulators.
AID1334208Effect on NOS2 mRNA expression in human SK-N-SH cells at EC10 by qPCR method relative to beta-actin2017Bioorganic & medicinal chemistry, 01-15, Volume: 25, Issue:2
Computer design, synthesis, and bioactivity analyses of drugs like fingolimod used in the treatment of multiple sclerosis.
AID1054250Immunomodulatory activity in multiple sclerosis patient assessed as decrease in peripheral blood lymphocyte count at 5 mg/kg, po2013Bioorganic & medicinal chemistry letters, Dec-01, Volume: 23, Issue:23
Modulators of the Sphingosine 1-phosphate receptor 1.
AID1300058Reduction in lymphocyte level in BALB/c mouse assessed as blood lymphocyte level at 30 mg/kg, po after 24 hrs by hematology analysis (Rvb = 5.13 to 8.02 10'3/mm3)2016ACS medicinal chemistry letters, Mar-10, Volume: 7, Issue:3
Identification and Preclinical Pharmacology of BMS-986104: A Differentiated S1P1 Receptor Modulator in Clinical Trials.
AID1334181Effect on MAL mRNA expression in human SK-N-SH cells at EC10 by qPCR method relative to beta-actin2017Bioorganic & medicinal chemistry, 01-15, Volume: 25, Issue:2
Computer design, synthesis, and bioactivity analyses of drugs like fingolimod used in the treatment of multiple sclerosis.
AID1334046Effect on RAF1 mRNA expression in human SH-SY5Y cells at EC10 by qPCR method relative to beta-actin2017Bioorganic & medicinal chemistry, 01-15, Volume: 25, Issue:2
Computer design, synthesis, and bioactivity analyses of drugs like fingolimod used in the treatment of multiple sclerosis.
AID1334047Effect on VEGFA mRNA expression in human SH-SY5Y cells at EC10 by qPCR method relative to beta-actin2017Bioorganic & medicinal chemistry, 01-15, Volume: 25, Issue:2
Computer design, synthesis, and bioactivity analyses of drugs like fingolimod used in the treatment of multiple sclerosis.
AID777397Cytotoxicity against Ph-positive human SUP-B15 cells after 72 hrs by vital dye exclusion/flow cytometric analysis2013ACS medicinal chemistry letters, Oct-10, Volume: 4, Issue:10
Design, Synthesis, and Anti-leukemic Activity of Stereochemically Defined Constrained Analogs of FTY720 (Gilenya).
AID1334163Effect on CXCL10 mRNA expression in human SK-N-SH cells at EC10 by qPCR method relative to beta-actin2017Bioorganic & medicinal chemistry, 01-15, Volume: 25, Issue:2
Computer design, synthesis, and bioactivity analyses of drugs like fingolimod used in the treatment of multiple sclerosis.
AID282271Displacement of [33P]sphingosine 1 phosphate from human S1P5 receptor expressed in CHO cells2004Journal of medicinal chemistry, Dec-30, Volume: 47, Issue:27
A rational utilization of high-throughput screening affords selective, orally bioavailable 1-benzyl-3-carboxyazetidine sphingosine-1-phosphate-1 receptor agonists.
AID1185032Induction of recombinant PP2A catalytic subunit (unknown origin) activity assessed as phosphate level at 5 uM relative to control2014ACS medicinal chemistry letters, Jul-10, Volume: 5, Issue:7
Novel FTY720-Based Compounds Stimulate Neurotrophin Expression and Phosphatase Activity in Dopaminergic Cells.
AID1334093Effect on PMP22 mRNA expression in human U118MG cells at EC10 by qPCR method relative to beta-actin2017Bioorganic & medicinal chemistry, 01-15, Volume: 25, Issue:2
Computer design, synthesis, and bioactivity analyses of drugs like fingolimod used in the treatment of multiple sclerosis.
AID1334065Effect on STAT3 mRNA expression in human SH-SY5Y cells at EC10 by qPCR method relative to beta-actin2017Bioorganic & medicinal chemistry, 01-15, Volume: 25, Issue:2
Computer design, synthesis, and bioactivity analyses of drugs like fingolimod used in the treatment of multiple sclerosis.
AID1334127Effect on APP mRNA expression in human U118MG cells at EC10 by qPCR method relative to beta-actin2017Bioorganic & medicinal chemistry, 01-15, Volume: 25, Issue:2
Computer design, synthesis, and bioactivity analyses of drugs like fingolimod used in the treatment of multiple sclerosis.
AID1890686Anti-inflammatory activity in MOG (35 to 55 residues)-induced experimental autoimmune encephalomyelitis mouse model assessed as reduction in spinal cord inflammation severity score by H&E staining based light microscopic analysis2022Bioorganic & medicinal chemistry letters, 05-15, Volume: 64Design, synthesis, and biological evaluation of polyphenol derivatives as DYRK1A inhibitors. The discovery of a potentially promising treatment for Multiple Sclerosis.
AID1334132Effect on STAT3 mRNA expression in human U118MG cells at EC10 by qPCR method relative to beta-actin2017Bioorganic & medicinal chemistry, 01-15, Volume: 25, Issue:2
Computer design, synthesis, and bioactivity analyses of drugs like fingolimod used in the treatment of multiple sclerosis.
AID1334202Effect on ADCY5 mRNA expression in human SK-N-SH cells at EC10 by qPCR method relative to beta-actin2017Bioorganic & medicinal chemistry, 01-15, Volume: 25, Issue:2
Computer design, synthesis, and bioactivity analyses of drugs like fingolimod used in the treatment of multiple sclerosis.
AID1901444Induction of lymphopenia in rat assessed as reduction in blood lymphocyte count at 1 mg/kg, po measured after 24 hrs2022Journal of medicinal chemistry, 02-24, Volume: 65, Issue:4
Discovery of Novel Sphingosine-1-Phosphate-1 Receptor Agonists for the Treatment of Multiple Sclerosis.
AID1334100Effect on IFNG mRNA expression in human U118MG cells at EC10 by qPCR method relative to beta-actin2017Bioorganic & medicinal chemistry, 01-15, Volume: 25, Issue:2
Computer design, synthesis, and bioactivity analyses of drugs like fingolimod used in the treatment of multiple sclerosis.
AID596404Immunosuppressive activity in BALB/c/C57BL/6 mouse T cells assessed as inhibition of alloantigen-induced cell proliferation after 96 hrs by measuring [3H]thymidine uptake by mixed lymphocyte reaction assay2011Journal of natural products, Apr-25, Volume: 74, Issue:4
Fingolimod (FTY720): a recently approved multiple sclerosis drug based on a fungal secondary metabolite.
AID1735813Reduction in circulating lymphocytes in Lewis rat blood assessed as effective dose after oral dosing measured at 24 hrs by hematology analyzer based analysis2019Journal of medicinal chemistry, 03-14, Volume: 62, Issue:5
Identification and Preclinical Pharmacology of ((1 R,3 S)-1-Amino-3-(( S)-6-(2-methoxyphenethyl)-5,6,7,8-tetrahydronaphthalen-2-yl)cyclopentyl)methanol (BMS-986166): A Differentiated Sphingosine-1-phosphate Receptor 1 (S1P
AID1300059Pulmonary toxicity in BALB/c mouse assessed as BAL protein levels at 0.5 mg/kg, po after 24 by hematology analysis (Rvb = 8.2 to 8.3 mg/dL)2016ACS medicinal chemistry letters, Mar-10, Volume: 7, Issue:3
Identification and Preclinical Pharmacology of BMS-986104: A Differentiated S1P1 Receptor Modulator in Clinical Trials.
AID1334101Effect on IL10 mRNA expression in human U118MG cells at EC10 by qPCR method relative to beta-actin2017Bioorganic & medicinal chemistry, 01-15, Volume: 25, Issue:2
Computer design, synthesis, and bioactivity analyses of drugs like fingolimod used in the treatment of multiple sclerosis.
AID596416Toxicity in human MGC803 cells xenografted nude mouse at 10 mg/kg for 20 days2011Journal of natural products, Apr-25, Volume: 74, Issue:4
Fingolimod (FTY720): a recently approved multiple sclerosis drug based on a fungal secondary metabolite.
AID588212Literature-mined compound from Fourches et al multi-species drug-induced liver injury (DILI) dataset, effect in rodents2010Chemical research in toxicology, Jan, Volume: 23, Issue:1
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
AID1179550Metabolic stability in rat hepatic microsomes assessed as parent compound remaining after 30 mins at 37 degC2014Bioorganic & medicinal chemistry, Aug-01, Volume: 22, Issue:15
Synthesis and SAR studies of benzyl ether derivatives as potent orally active S1P₁ agonists.
AID588211Literature-mined compound from Fourches et al multi-species drug-induced liver injury (DILI) dataset, effect in humans2010Chemical research in toxicology, Jan, Volume: 23, Issue:1
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
AID1334210Effect on S1PR1 mRNA expression in human SK-N-SH cells at EC10 by qPCR method relative to beta-actin2017Bioorganic & medicinal chemistry, 01-15, Volume: 25, Issue:2
Computer design, synthesis, and bioactivity analyses of drugs like fingolimod used in the treatment of multiple sclerosis.
AID1596334Anti-sclerotic activity in MOG/CFA-induced zebra fish EAE model assessed as reduction in lesion score at 1 mg/kg, po measured for 7 days2019European journal of medicinal chemistry, Jul-15, Volume: 174InCl
AID1735871Immunosuppressive activity in MOG (35 to 55 residues)/pertussis toxin-induced experimental autoimmune encephalomyelitis C57BL/6 mouse model assessed as reduction in formation of inflammatory lesions in CNS at 1 mg/kg, po QD starting from day 1 post immuni2019Journal of medicinal chemistry, 03-14, Volume: 62, Issue:5
Identification and Preclinical Pharmacology of ((1 R,3 S)-1-Amino-3-(( S)-6-(2-methoxyphenethyl)-5,6,7,8-tetrahydronaphthalen-2-yl)cyclopentyl)methanol (BMS-986166): A Differentiated Sphingosine-1-phosphate Receptor 1 (S1P
AID1334066Effect on ADCY5 mRNA expression in human SH-SY5Y cells at EC10 by qPCR method relative to beta-actin2017Bioorganic & medicinal chemistry, 01-15, Volume: 25, Issue:2
Computer design, synthesis, and bioactivity analyses of drugs like fingolimod used in the treatment of multiple sclerosis.
AID282268Displacement of [33P]sphingosine 1 phosphate from human S1P2 receptor expressed in CHO cells2004Journal of medicinal chemistry, Dec-30, Volume: 47, Issue:27
A rational utilization of high-throughput screening affords selective, orally bioavailable 1-benzyl-3-carboxyazetidine sphingosine-1-phosphate-1 receptor agonists.
AID1334086Effect on GRM1 mRNA expression in human SH-SY5Y cells at EC10 by qPCR method relative to beta-actin2017Bioorganic & medicinal chemistry, 01-15, Volume: 25, Issue:2
Computer design, synthesis, and bioactivity analyses of drugs like fingolimod used in the treatment of multiple sclerosis.
AID305219Effect on rate of phosphorylation of human recombinant SPHK2 expressed in HEK293 cells2007Bioorganic & medicinal chemistry letters, Jan-15, Volume: 17, Issue:2
Constrained azacyclic analogues of the immunomodulatory agent FTY720 as molecular probes for sphingosine 1-phosphate receptors.
AID1334183Effect on VEGFA mRNA expression in human SK-N-SH cells at EC10 by qPCR method relative to beta-actin2017Bioorganic & medicinal chemistry, 01-15, Volume: 25, Issue:2
Computer design, synthesis, and bioactivity analyses of drugs like fingolimod used in the treatment of multiple sclerosis.
AID1334028Effect on CXCL10 mRNA expression in human SH-SY5Y cells at EC10 by qPCR method relative to beta-actin2017Bioorganic & medicinal chemistry, 01-15, Volume: 25, Issue:2
Computer design, synthesis, and bioactivity analyses of drugs like fingolimod used in the treatment of multiple sclerosis.
AID1334129Effect on JUN mRNA expression in human U118MG cells at EC10 by qPCR method relative to beta-actin2017Bioorganic & medicinal chemistry, 01-15, Volume: 25, Issue:2
Computer design, synthesis, and bioactivity analyses of drugs like fingolimod used in the treatment of multiple sclerosis.
AID1334084Effect on CFLAR mRNA expression in human SH-SY5Y cells at EC10 by qPCR method relative to beta-actin2017Bioorganic & medicinal chemistry, 01-15, Volume: 25, Issue:2
Computer design, synthesis, and bioactivity analyses of drugs like fingolimod used in the treatment of multiple sclerosis.
AID1334072Effect on NOS2 mRNA expression in human SH-SY5Y cells at EC10 by qPCR method relative to beta-actin2017Bioorganic & medicinal chemistry, 01-15, Volume: 25, Issue:2
Computer design, synthesis, and bioactivity analyses of drugs like fingolimod used in the treatment of multiple sclerosis.
AID1334218Effect on AKT1 mRNA expression in human SK-N-SH cells at EC10 by qPCR method relative to beta-actin2017Bioorganic & medicinal chemistry, 01-15, Volume: 25, Issue:2
Computer design, synthesis, and bioactivity analyses of drugs like fingolimod used in the treatment of multiple sclerosis.
AID1334060Effect on HDAC1 mRNA expression in human SH-SY5Y cells at EC10 by qPCR method relative to beta-actin2017Bioorganic & medicinal chemistry, 01-15, Volume: 25, Issue:2
Computer design, synthesis, and bioactivity analyses of drugs like fingolimod used in the treatment of multiple sclerosis.
AID1334027Effect on CSF1 mRNA expression in human SH-SY5Y cells at EC10 by qPCR method relative to beta-actin2017Bioorganic & medicinal chemistry, 01-15, Volume: 25, Issue:2
Computer design, synthesis, and bioactivity analyses of drugs like fingolimod used in the treatment of multiple sclerosis.
AID1300089Reduction in Fcgr4 gene expression in SCID mouse with CD45RBhiCD4+ T-cell transfer-induced colitis model of inflammatory bowel disease at 5 mg/kg, po dosed every other day for 5 weeks by RT-PCR method2016ACS medicinal chemistry letters, Mar-10, Volume: 7, Issue:3
Identification and Preclinical Pharmacology of BMS-986104: A Differentiated S1P1 Receptor Modulator in Clinical Trials.
AID1730794AUC ratio in orally dosed Sprague-Dawley rat blood assessed as phosphate metabolite to parent compound2021Journal of medicinal chemistry, 02-11, Volume: 64, Issue:3
Bicyclic Ligand-Biased Agonists of S1P
AID1474287Toxicity in human assessed as reduction in heart rate at 1.25 mg measured for 2 days2017Journal of medicinal chemistry, 07-13, Volume: 60, Issue:13
Modulators of Sphingosine-1-phosphate Pathway Biology: Recent Advances of Sphingosine-1-phosphate Receptor 1 (S1P
AID1300060Pulmonary toxicity in BALB/c mouse assessed as BAL protein levels at 10 mg/kg, po after 24 by hematology analysis (Rvb = 8.2 to 8.3 mg/dL)2016ACS medicinal chemistry letters, Mar-10, Volume: 7, Issue:3
Identification and Preclinical Pharmacology of BMS-986104: A Differentiated S1P1 Receptor Modulator in Clinical Trials.
AID1334073Effect on OPRD1 mRNA expression in human SH-SY5Y cells at EC10 by qPCR method relative to beta-actin2017Bioorganic & medicinal chemistry, 01-15, Volume: 25, Issue:2
Computer design, synthesis, and bioactivity analyses of drugs like fingolimod used in the treatment of multiple sclerosis.
AID1296238Reduction in clinical score in C57BL/6 mouse experimental autoimmune encephalomyelitis model of multiple sclerosis at 1 mg/kg, po qd for 24 days started from day of immunization measured 3 times per week of compound dosing2016Journal of medicinal chemistry, Mar-24, Volume: 59, Issue:6
Potent and Selective Agonists of Sphingosine 1-Phosphate 1 (S1P1): Discovery and SAR of a Novel Isoxazole Based Series.
AID1334102Effect on IL1B mRNA expression in human U118MG cells at EC10 by qPCR method relative to beta-actin2017Bioorganic & medicinal chemistry, 01-15, Volume: 25, Issue:2
Computer design, synthesis, and bioactivity analyses of drugs like fingolimod used in the treatment of multiple sclerosis.
AID1497422Anti-inflammatory activity in MOG (35 to 55 residues)-induced EAE C57BL/6 mouse model assessed as inhibition of development of clinical symptoms at 1 mg/kg, po qd measured on day 8 post MOG (35 to 55 residues) immunization2018Journal of medicinal chemistry, 06-28, Volume: 61, Issue:12
Design and Synthesis of a Novel Series of Orally Bioavailable, CNS-Penetrant, Isoform Selective Phosphoinositide 3-Kinase γ (PI3Kγ) Inhibitors with Potential for the Treatment of Multiple Sclerosis (MS).
AID1334114Effect on MAL mRNA expression in human U118MG cells at EC10 by qPCR method relative to beta-actin2017Bioorganic & medicinal chemistry, 01-15, Volume: 25, Issue:2
Computer design, synthesis, and bioactivity analyses of drugs like fingolimod used in the treatment of multiple sclerosis.
AID362337Antiangiogenic activity in chick embryo chorioallantoic membrane assessed as number of eggs showing 3 mm avascular zone at 1 ug2008Bioorganic & medicinal chemistry, Aug-15, Volume: 16, Issue:16
TX-2152: a conformationally rigid and electron-rich diyne analogue of FTY720 with in vivo antiangiogenic activity.
AID1532400Immunosuppressive activity in human assessed as decrease in peripheral blood lymphocytes at 1 mg measured over 2 days relative to control2018Bioorganic & medicinal chemistry letters, 12-15, Volume: 28, Issue:23-24
An update on sphingosine-1-phosphate receptor 1 modulators.
AID1334017Agonist activity at sphingosine-1-phosphate receptor in human U118MG cells assessed as increase in cAMP level at EC10 by direct immunoassay2017Bioorganic & medicinal chemistry, 01-15, Volume: 25, Issue:2
Computer design, synthesis, and bioactivity analyses of drugs like fingolimod used in the treatment of multiple sclerosis.
AID1334025Effect on CCL2 mRNA expression in human SH-SY5Y cells at EC10 by qPCR method relative to beta-actin2017Bioorganic & medicinal chemistry, 01-15, Volume: 25, Issue:2
Computer design, synthesis, and bioactivity analyses of drugs like fingolimod used in the treatment of multiple sclerosis.
AID1334087Effect on GRM5 mRNA expression in human SH-SY5Y cells at EC10 by qPCR method relative to beta-actin2017Bioorganic & medicinal chemistry, 01-15, Volume: 25, Issue:2
Computer design, synthesis, and bioactivity analyses of drugs like fingolimod used in the treatment of multiple sclerosis.
AID1054251Immunomodulatory activity in multiple sclerosis patient assessed as decrease in peripheral blood lymphocyte count at 1.25 mg/kg, po2013Bioorganic & medicinal chemistry letters, Dec-01, Volume: 23, Issue:23
Modulators of the Sphingosine 1-phosphate receptor 1.
AID1334103Effect on IL6 mRNA expression in human U118MG cells at EC10 by qPCR method relative to beta-actin2017Bioorganic & medicinal chemistry, 01-15, Volume: 25, Issue:2
Computer design, synthesis, and bioactivity analyses of drugs like fingolimod used in the treatment of multiple sclerosis.
AID1334215Effect on AGT mRNA expression in human SK-N-SH cells at EC10 by qPCR method relative to beta-actin2017Bioorganic & medicinal chemistry, 01-15, Volume: 25, Issue:2
Computer design, synthesis, and bioactivity analyses of drugs like fingolimod used in the treatment of multiple sclerosis.
AID1334122Effect on EPHA1 mRNA expression in human U118MG cells at EC10 by qPCR method relative to beta-actin2017Bioorganic & medicinal chemistry, 01-15, Volume: 25, Issue:2
Computer design, synthesis, and bioactivity analyses of drugs like fingolimod used in the treatment of multiple sclerosis.
AID1334085Effect on PIK3CG mRNA expression in human SH-SY5Y cells at EC10 by qPCR method relative to beta-actin2017Bioorganic & medicinal chemistry, 01-15, Volume: 25, Issue:2
Computer design, synthesis, and bioactivity analyses of drugs like fingolimod used in the treatment of multiple sclerosis.
AID1334157Effect on PMP22 mRNA expression in human SK-N-SH cells at EC10 by qPCR method relative to beta-actin2017Bioorganic & medicinal chemistry, 01-15, Volume: 25, Issue:2
Computer design, synthesis, and bioactivity analyses of drugs like fingolimod used in the treatment of multiple sclerosis.
AID1257231Immunosuppressive activity in mouse assessed as reduction of WBC level in peripheral blood assessed per 10'6 cells at 1.25 mg/kg, ip after 24 hrs by flow cytometry (Rvb = 8.94 +/- 0.59 ml)2015Bioorganic & medicinal chemistry letters, Nov-15, Volume: 25, Issue:22
New fluorinated agonists for targeting the sphingosin-1-phosphate receptor 1 (S1P(1)).
AID1300057Reduction in lymphocyte level in BALB/c mouse assessed as blood lymphocyte level at 10 mg/kg, po after 24 hrs by hematology analysis (Rvb = 5.13 to 8.02 10'3/mm3)2016ACS medicinal chemistry letters, Mar-10, Volume: 7, Issue:3
Identification and Preclinical Pharmacology of BMS-986104: A Differentiated S1P1 Receptor Modulator in Clinical Trials.
AID1334020Effect on PTGDR mRNA expression in human SK-N-SH cells at EC10 by qPCR method relative to beta-actin2017Bioorganic & medicinal chemistry, 01-15, Volume: 25, Issue:2
Computer design, synthesis, and bioactivity analyses of drugs like fingolimod used in the treatment of multiple sclerosis.
AID1334071Effect on GNAS mRNA expression in human SH-SY5Y cells at EC10 by qPCR method relative to beta-actin2017Bioorganic & medicinal chemistry, 01-15, Volume: 25, Issue:2
Computer design, synthesis, and bioactivity analyses of drugs like fingolimod used in the treatment of multiple sclerosis.
AID1179548AUC (0 to 48 hrs) in rat at 1 mg/kg, po2014Bioorganic & medicinal chemistry, Aug-01, Volume: 22, Issue:15
Synthesis and SAR studies of benzyl ether derivatives as potent orally active S1P₁ agonists.
AID1334195Effect on FOXP3 mRNA expression in human SK-N-SH cells at EC10 by qPCR method relative to beta-actin2017Bioorganic & medicinal chemistry, 01-15, Volume: 25, Issue:2
Computer design, synthesis, and bioactivity analyses of drugs like fingolimod used in the treatment of multiple sclerosis.
AID1334045Effect on MAL mRNA expression in human SH-SY5Y cells at EC10 by qPCR method relative to beta-actin2017Bioorganic & medicinal chemistry, 01-15, Volume: 25, Issue:2
Computer design, synthesis, and bioactivity analyses of drugs like fingolimod used in the treatment of multiple sclerosis.
AID1334115Effect on RAF1 mRNA expression in human U118MG cells at EC10 by qPCR method relative to beta-actin2017Bioorganic & medicinal chemistry, 01-15, Volume: 25, Issue:2
Computer design, synthesis, and bioactivity analyses of drugs like fingolimod used in the treatment of multiple sclerosis.
AID268317Median graft survival time in Lewis rat skin allograft model at 1 mg/kg/day, po2006Bioorganic & medicinal chemistry letters, Jul-15, Volume: 16, Issue:14
Discovery of 3-arylpropionic acids as potent agonists of sphingosine-1-phosphate receptor-1 (S1P1) with high selectivity against all other known S1P receptor subtypes.
AID1334194Effect on APP mRNA expression in human SK-N-SH cells at EC10 by qPCR method relative to beta-actin2017Bioorganic & medicinal chemistry, 01-15, Volume: 25, Issue:2
Computer design, synthesis, and bioactivity analyses of drugs like fingolimod used in the treatment of multiple sclerosis.
AID1532419Immunosuppressive activity in po dosed human assessed as decrease in peripheral blood lymphocyte count measured after 24 hrs2018Bioorganic & medicinal chemistry letters, 12-15, Volume: 28, Issue:23-24
An update on sphingosine-1-phosphate receptor 1 modulators.
AID1890688Anti-inflammatory activity in MOG (35 to 55 residues)-induced experimental autoimmune encephalomyelitis mouse model assessed as reduction in spinal cord axonal neurodegeneration severity score by Bielschowsky silver staining based light microscopic analys2022Bioorganic & medicinal chemistry letters, 05-15, Volume: 64Design, synthesis, and biological evaluation of polyphenol derivatives as DYRK1A inhibitors. The discovery of a potentially promising treatment for Multiple Sclerosis.
AID1334118Effect on ITGB2 mRNA expression in human U118MG cells at EC10 by qPCR method relative to beta-actin2017Bioorganic & medicinal chemistry, 01-15, Volume: 25, Issue:2
Computer design, synthesis, and bioactivity analyses of drugs like fingolimod used in the treatment of multiple sclerosis.
AID1185982Cmax in Sprague-Dawley rat at 3 mg/kg, po2014European journal of medicinal chemistry, Oct-06, Volume: 85Discovery of oxazole and triazole derivatives as potent and selective S1P(1) agonists through pharmacophore-guided design.
AID1334013Cytotoxicity against human SH-SY5Y cells measured after 24 hrs by crystal-violet staining based assay2017Bioorganic & medicinal chemistry, 01-15, Volume: 25, Issue:2
Computer design, synthesis, and bioactivity analyses of drugs like fingolimod used in the treatment of multiple sclerosis.
AID240251Agonism of human S1P-5 receptor expressed in CHO cells, 90-120 min in pH 7.4 using [35S]GTP-gamma-S as radioligand2005Journal of medicinal chemistry, Aug-11, Volume: 48, Issue:16
Novel immunomodulator FTY720 is phosphorylated in rats and humans to form a single stereoisomer. Identification, chemical proof, and biological characterization of the biologically active species and its enantiomer.
AID777394Cytotoxicity against Ph-negative human BLIN-1 cells after 72 hrs by vital dye exclusion/flow cytometric analysis2013ACS medicinal chemistry letters, Oct-10, Volume: 4, Issue:10
Design, Synthesis, and Anti-leukemic Activity of Stereochemically Defined Constrained Analogs of FTY720 (Gilenya).
AID1271835Agonist activity at human S1P1 receptor expressed in EDG1-bla U2OS cells incubated for 18 hrs prior to GenBlazer substrate addition by beta-arrestin recruitment assay2016Bioorganic & medicinal chemistry letters, Jan-15, Volume: 26, Issue:2
Late-stage optimization of a tercyclic class of S1P3-sparing, S1P1 receptor agonists.
AID1917908Anticancer activity against human SK-N-AS cells assessed as reduction in cell viability incubated for 48 hrs by resazurin dye based fluorescence assay2022Bioorganic & medicinal chemistry, 11-01, Volume: 73Multiple approaches to repurposing drugs for neuroblastoma.
AID1185986Apparent oral clearance in Sprague-Dawley rat at 3 mg/kg, po2014European journal of medicinal chemistry, Oct-06, Volume: 85Discovery of oxazole and triazole derivatives as potent and selective S1P(1) agonists through pharmacophore-guided design.
AID1185030Induction of recombinant PP2A catalytic subunit (unknown origin) activity assessed as phosphate level using threonine-phosphopeptide at 5 uM2014ACS medicinal chemistry letters, Jul-10, Volume: 5, Issue:7
Novel FTY720-Based Compounds Stimulate Neurotrophin Expression and Phosphatase Activity in Dopaminergic Cells.
AID240249Agonism of human S1P-3 receptor expressed in CHO cells, 90-120 min in pH 7.4 using [35S]GTP-gamma-S as radioligand2005Journal of medicinal chemistry, Aug-11, Volume: 48, Issue:16
Novel immunomodulator FTY720 is phosphorylated in rats and humans to form a single stereoisomer. Identification, chemical proof, and biological characterization of the biologically active species and its enantiomer.
AID1422491Downregulation of CD98 expression in mouse FL5.12 cells at 2.5 uM after 3 hrs by DAPI staining-based FACS analysis relative to control2018European journal of medicinal chemistry, Nov-05, Volume: 159In search of constrained FTY720 and phytosphingosine analogs as dual acting anticancer agents targeting metabolic and epigenetic pathways.
AID1176661Reduction in disease severity in C57Bl/6 mouse experimental autoimmune encephalomyelitis model of multiple sclerosis at 1 mg/kg dosed once daily beginning on day 18 and continued to day 372014ACS medicinal chemistry letters, Dec-11, Volume: 5, Issue:12
Discovery of APD334: Design of a Clinical Stage Functional Antagonist of the Sphingosine-1-phosphate-1 Receptor.
AID1334125Effect on HLA-DRB1 mRNA expression in human U118MG cells at EC10 by qPCR method relative to beta-actin2017Bioorganic & medicinal chemistry, 01-15, Volume: 25, Issue:2
Computer design, synthesis, and bioactivity analyses of drugs like fingolimod used in the treatment of multiple sclerosis.
AID596407Immunosuppressive activity in F344 rat lateral thorax transplanted with dorsal skin of LEW rat assessed as increase of skin graft survival time at 3 mg/kg, ip2011Journal of natural products, Apr-25, Volume: 74, Issue:4
Fingolimod (FTY720): a recently approved multiple sclerosis drug based on a fungal secondary metabolite.
AID1334063Effect on MYC mRNA expression in human SH-SY5Y cells at EC10 by qPCR method relative to beta-actin2017Bioorganic & medicinal chemistry, 01-15, Volume: 25, Issue:2
Computer design, synthesis, and bioactivity analyses of drugs like fingolimod used in the treatment of multiple sclerosis.
AID1334018Agonist activity at sphingosine-1-phosphate receptor (unknown origin) expressed in HEK293 cells assessed as increase in cAMP level at EC10 after 18 hrs by CRE-responsive renilla luciferase reporter gene assay2017Bioorganic & medicinal chemistry, 01-15, Volume: 25, Issue:2
Computer design, synthesis, and bioactivity analyses of drugs like fingolimod used in the treatment of multiple sclerosis.
AID1735847AUC ratio in orally dosed cynomolgus monkey blood assessed as phosphate metabolite to parent compound2019Journal of medicinal chemistry, 03-14, Volume: 62, Issue:5
Identification and Preclinical Pharmacology of ((1 R,3 S)-1-Amino-3-(( S)-6-(2-methoxyphenethyl)-5,6,7,8-tetrahydronaphthalen-2-yl)cyclopentyl)methanol (BMS-986166): A Differentiated Sphingosine-1-phosphate Receptor 1 (S1P
AID1334179Effect on BCL2 mRNA expression in human SK-N-SH cells at EC10 by qPCR method relative to beta-actin2017Bioorganic & medicinal chemistry, 01-15, Volume: 25, Issue:2
Computer design, synthesis, and bioactivity analyses of drugs like fingolimod used in the treatment of multiple sclerosis.
AID596409Antiproliferative activity against human MCF7 cells assessed as growth inhibition after 78 hrs by WST-1 assay2011Journal of natural products, Apr-25, Volume: 74, Issue:4
Fingolimod (FTY720): a recently approved multiple sclerosis drug based on a fungal secondary metabolite.
AID1334227Effect on PTGDR mRNA expression in human U118MG cells at EC10 by qPCR method relative to beta-actin2017Bioorganic & medicinal chemistry, 01-15, Volume: 25, Issue:2
Computer design, synthesis, and bioactivity analyses of drugs like fingolimod used in the treatment of multiple sclerosis.
AID1890687Anti-inflammatory activity in MOG (35 to 55 residues)-induced experimental autoimmune encephalomyelitis mouse model assessed as reduction in spinal cord demyelination severity score by Luxol fast blue staining based light microscopic analysis2022Bioorganic & medicinal chemistry letters, 05-15, Volume: 64Design, synthesis, and biological evaluation of polyphenol derivatives as DYRK1A inhibitors. The discovery of a potentially promising treatment for Multiple Sclerosis.
AID596414Antiproliferative activity human LNCAP-AI cells assessed as growth inhibition after 78 hrs by WST-1 assay2011Journal of natural products, Apr-25, Volume: 74, Issue:4
Fingolimod (FTY720): a recently approved multiple sclerosis drug based on a fungal secondary metabolite.
AID1735846AUC ratio in orally dosed Beagle dog blood assessed as phosphate metabolite to parent compound2019Journal of medicinal chemistry, 03-14, Volume: 62, Issue:5
Identification and Preclinical Pharmacology of ((1 R,3 S)-1-Amino-3-(( S)-6-(2-methoxyphenethyl)-5,6,7,8-tetrahydronaphthalen-2-yl)cyclopentyl)methanol (BMS-986166): A Differentiated Sphingosine-1-phosphate Receptor 1 (S1P
AID1532426Half life in human2018Bioorganic & medicinal chemistry letters, 12-15, Volume: 28, Issue:23-24
An update on sphingosine-1-phosphate receptor 1 modulators.
AID721980Immunomodulatory activity in C57Bl/6 mouse assessed as induction of lymphopenia at 1 mg/kg, po measured after 6 hrs2013Bioorganic & medicinal chemistry letters, Jan-15, Volume: 23, Issue:2
Exploring amino acids derivatives as potent, selective, and direct agonists of sphingosine-1-phosphate receptor subtype-1.
AID1176666Induction of body weight regain in Lewis rat collagen-induced arthritis model at 1 mg/kg, po qd measured on day 17 (Rvb = 160.3 +/- 2.3 g)2014ACS medicinal chemistry letters, Dec-11, Volume: 5, Issue:12
Discovery of APD334: Design of a Clinical Stage Functional Antagonist of the Sphingosine-1-phosphate-1 Receptor.
AID1334068Effect on ADRB2 mRNA expression in human SH-SY5Y cells at EC10 by qPCR method relative to beta-actin2017Bioorganic & medicinal chemistry, 01-15, Volume: 25, Issue:2
Computer design, synthesis, and bioactivity analyses of drugs like fingolimod used in the treatment of multiple sclerosis.
AID1334186Effect on VCAM1 mRNA expression in human SK-N-SH cells at EC10 by qPCR method relative to beta-actin2017Bioorganic & medicinal chemistry, 01-15, Volume: 25, Issue:2
Computer design, synthesis, and bioactivity analyses of drugs like fingolimod used in the treatment of multiple sclerosis.
AID1185035Neuroprotective activity in mouse MN9D cells assessed as cell division at 0.04 to 0.16 uM after 72 hrs by DAPI staining (Rvb = 100 +/- 4.15%)2014ACS medicinal chemistry letters, Jul-10, Volume: 5, Issue:7
Novel FTY720-Based Compounds Stimulate Neurotrophin Expression and Phosphatase Activity in Dopaminergic Cells.
AID1179544Induction of bradycardia in Wistar Imamichi rat assessed as reduction in heart rate 10 mg/kg, po after 24 hrs2014Bioorganic & medicinal chemistry, Aug-01, Volume: 22, Issue:15
Synthesis and SAR studies of benzyl ether derivatives as potent orally active S1P₁ agonists.
AID1185984Half life in Sprague-Dawley rat at 3 mg/kg, po2014European journal of medicinal chemistry, Oct-06, Volume: 85Discovery of oxazole and triazole derivatives as potent and selective S1P(1) agonists through pharmacophore-guided design.
AID1334120Effect on MMP9 mRNA expression in human U118MG cells at EC10 by qPCR method relative to beta-actin2017Bioorganic & medicinal chemistry, 01-15, Volume: 25, Issue:2
Computer design, synthesis, and bioactivity analyses of drugs like fingolimod used in the treatment of multiple sclerosis.
AID1334190Effect on EPHA1 mRNA expression in human SK-N-SH cells at EC10 by qPCR method relative to beta-actin2017Bioorganic & medicinal chemistry, 01-15, Volume: 25, Issue:2
Computer design, synthesis, and bioactivity analyses of drugs like fingolimod used in the treatment of multiple sclerosis.
AID1334216Effect on FGF2 mRNA expression in human SK-N-SH cells at EC10 by qPCR method relative to beta-actin2017Bioorganic & medicinal chemistry, 01-15, Volume: 25, Issue:2
Computer design, synthesis, and bioactivity analyses of drugs like fingolimod used in the treatment of multiple sclerosis.
AID1334156Effect on MAG mRNA expression in human SK-N-SH cells at EC10 by qPCR method relative to beta-actin2017Bioorganic & medicinal chemistry, 01-15, Volume: 25, Issue:2
Computer design, synthesis, and bioactivity analyses of drugs like fingolimod used in the treatment of multiple sclerosis.
AID1334053Effect on EDNRA mRNA expression in human SH-SY5Y cells at EC10 by qPCR method relative to beta-actin2017Bioorganic & medicinal chemistry, 01-15, Volume: 25, Issue:2
Computer design, synthesis, and bioactivity analyses of drugs like fingolimod used in the treatment of multiple sclerosis.
AID1334012Agonist activity at sphingosine-1-phosphate receptor in human SH-SY5Y cells assessed as increase in cAMP level at EC10 by direct immunoassay2017Bioorganic & medicinal chemistry, 01-15, Volume: 25, Issue:2
Computer design, synthesis, and bioactivity analyses of drugs like fingolimod used in the treatment of multiple sclerosis.
AID1846065Antitumor activity against human D341 Med cells assessed as reduction in cell viability incubated for 24 hrs by Alamar blue assay2021European journal of medicinal chemistry, Apr-05, Volume: 215Medulloblastoma drugs in development: Current leads, trials and drawbacks.
AID282269Displacement of [33P]sphingosine 1 phosphate from human S1P3 receptor expressed in CHO cells2004Journal of medicinal chemistry, Dec-30, Volume: 47, Issue:27
A rational utilization of high-throughput screening affords selective, orally bioavailable 1-benzyl-3-carboxyazetidine sphingosine-1-phosphate-1 receptor agonists.
AID192200Mean lymph node weight ratio of intra-subject allogenic to syngeneic splenocyte challenges in rat 0.3 mpk/day s.c.2004Bioorganic & medicinal chemistry letters, Jun-21, Volume: 14, Issue:12
Potent S1P receptor agonists replicate the pharmacologic actions of the novel immune modulator FTY720.
AID1334021Effect on MAG mRNA expression in human SH-SY5Y cells at EC10 by qPCR method relative to beta-actin2017Bioorganic & medicinal chemistry, 01-15, Volume: 25, Issue:2
Computer design, synthesis, and bioactivity analyses of drugs like fingolimod used in the treatment of multiple sclerosis.
AID1627821Downregulation of CD98 expression level in mouse FL5.12A cells at 2.5 uM measured at 3 hrs by flow cytometric analysis2016Bioorganic & medicinal chemistry, 09-15, Volume: 24, Issue:18
Effects of stereochemistry, saturation, and hydrocarbon chain length on the ability of synthetic constrained azacyclic sphingolipids to trigger nutrient transporter down-regulation, vacuolation, and cell death.
AID1334149Effect on CFLAR mRNA expression in human U118MG cells at EC10 by qPCR method relative to beta-actin2017Bioorganic & medicinal chemistry, 01-15, Volume: 25, Issue:2
Computer design, synthesis, and bioactivity analyses of drugs like fingolimod used in the treatment of multiple sclerosis.
AID473706Induction of human SphK2 phosphorylation2010Bioorganic & medicinal chemistry letters, Apr-01, Volume: 20, Issue:7
Stereochemistry-activity relationship of orally active tetralin S1P agonist prodrugs.
AID1334051Effect on MMP9 mRNA expression in human SH-SY5Y cells at EC10 by qPCR method relative to beta-actin2017Bioorganic & medicinal chemistry, 01-15, Volume: 25, Issue:2
Computer design, synthesis, and bioactivity analyses of drugs like fingolimod used in the treatment of multiple sclerosis.
AID240250Agonism of human S1P-4 receptor expressed in CHO cells, 90-120 min in pH 7.4 using [35S]GTP-gamma-S as radioligand2005Journal of medicinal chemistry, Aug-11, Volume: 48, Issue:16
Novel immunomodulator FTY720 is phosphorylated in rats and humans to form a single stereoisomer. Identification, chemical proof, and biological characterization of the biologically active species and its enantiomer.
AID1334081Effect on FGF2 mRNA expression in human SH-SY5Y cells at EC10 by qPCR method relative to beta-actin2017Bioorganic & medicinal chemistry, 01-15, Volume: 25, Issue:2
Computer design, synthesis, and bioactivity analyses of drugs like fingolimod used in the treatment of multiple sclerosis.
AID1334054Effect on EPHA1 mRNA expression in human SH-SY5Y cells at EC10 by qPCR method relative to beta-actin2017Bioorganic & medicinal chemistry, 01-15, Volume: 25, Issue:2
Computer design, synthesis, and bioactivity analyses of drugs like fingolimod used in the treatment of multiple sclerosis.
AID706334Increase in allograft survival in stringent Dark Agouti to Lewis rat heterotopic vascular heart allotransplantation model assessed as allograft mean survival time at 0.1 mg/kg, po qd co-treated with 10 mg/kg, po bid sotrastaurin2012Journal of medicinal chemistry, Nov-26, Volume: 55, Issue:22
An oral sphingosine 1-phosphate receptor 1 (S1P(1)) antagonist prodrug with efficacy in vivo: discovery, synthesis, and evaluation.
AID671369Immunosuppressant activity in collagen-induced Lewis rat arthritis model assessed as reduction in joint inflammation at 1 mg/kg, po qd2012Bioorganic & medicinal chemistry letters, Jul-01, Volume: 22, Issue:13
Fused tricyclic indoles as S1P₁ agonists with robust efficacy in animal models of autoimmune disease.
AID1370505Agonist activity at human S1P3 receptor expressed in CHO cells assessed as increase in calcium flux by aequorin-derived luminescence assay2018Bioorganic & medicinal chemistry letters, 02-01, Volume: 28, Issue:3
Spiro-1-benzofuranpiperidinylalkanoic acids as a novel and selective sphingosine S1P
AID1185036Neuroprotective activity in mouse MN9D cells assessed as stimulation of BDNF expression at 0.16 uM after 24 hrs2014ACS medicinal chemistry letters, Jul-10, Volume: 5, Issue:7
Novel FTY720-Based Compounds Stimulate Neurotrophin Expression and Phosphatase Activity in Dopaminergic Cells.
AID1334222Effect on GRM5 mRNA expression in human SK-N-SH cells at EC10 by qPCR method relative to beta-actin2017Bioorganic & medicinal chemistry, 01-15, Volume: 25, Issue:2
Computer design, synthesis, and bioactivity analyses of drugs like fingolimod used in the treatment of multiple sclerosis.
AID475242Immunomodulatory activity in ip dosed BALB/c mouse assessed as reduction in lymphocyte using FITC-conjugated hamster antimouse CD3e antibody by flow cytometry2010Journal of medicinal chemistry, Apr-22, Volume: 53, Issue:8
Removal of sphingosine 1-phosphate receptor-3 (S1P(3)) agonism is essential, but inadequate to obtain immunomodulating 2-aminopropane-1,3-diol S1P(1) agonists with reduced effect on heart rate.
AID1334147Effect on FGF2 mRNA expression in human U118MG cells at EC10 by qPCR method relative to beta-actin2017Bioorganic & medicinal chemistry, 01-15, Volume: 25, Issue:2
Computer design, synthesis, and bioactivity analyses of drugs like fingolimod used in the treatment of multiple sclerosis.
AID1334059Effect on FOXP3 mRNA expression in human SH-SY5Y cells at EC10 by qPCR method relative to beta-actin2017Bioorganic & medicinal chemistry, 01-15, Volume: 25, Issue:2
Computer design, synthesis, and bioactivity analyses of drugs like fingolimod used in the treatment of multiple sclerosis.
AID1334133Effect on ADCY5 mRNA expression in human U118MG cells at EC10 by qPCR method relative to beta-actin2017Bioorganic & medicinal chemistry, 01-15, Volume: 25, Issue:2
Computer design, synthesis, and bioactivity analyses of drugs like fingolimod used in the treatment of multiple sclerosis.
AID777389Cytotoxicity against Ph-negative human NALM6 cells after 72 hrs by vital dye exclusion/flow cytometric analysis2013ACS medicinal chemistry letters, Oct-10, Volume: 4, Issue:10
Design, Synthesis, and Anti-leukemic Activity of Stereochemically Defined Constrained Analogs of FTY720 (Gilenya).
AID282276Decrease in peripheral blood lymphocytes in po dosed mouse after 3 hrs2004Journal of medicinal chemistry, Dec-30, Volume: 47, Issue:27
A rational utilization of high-throughput screening affords selective, orally bioavailable 1-benzyl-3-carboxyazetidine sphingosine-1-phosphate-1 receptor agonists.
AID1334029Effect on IFNG mRNA expression in human SH-SY5Y cells at EC10 by qPCR method relative to beta-actin2017Bioorganic & medicinal chemistry, 01-15, Volume: 25, Issue:2
Computer design, synthesis, and bioactivity analyses of drugs like fingolimod used in the treatment of multiple sclerosis.
AID1846066Antitumor activity against human D384 Med cells assessed as reduction in cell viability incubated for 24 hrs by Alamar blue assay2021European journal of medicinal chemistry, Apr-05, Volume: 215Medulloblastoma drugs in development: Current leads, trials and drawbacks.
AID1334080Effect on AGT mRNA expression in human SH-SY5Y cells at EC10 by qPCR method relative to beta-actin2017Bioorganic & medicinal chemistry, 01-15, Volume: 25, Issue:2
Computer design, synthesis, and bioactivity analyses of drugs like fingolimod used in the treatment of multiple sclerosis.
AID1185988Cardiotoxicity in Sprague-Dawley rat assessed as change in heart rate at 10 mg/kg, po2014European journal of medicinal chemistry, Oct-06, Volume: 85Discovery of oxazole and triazole derivatives as potent and selective S1P(1) agonists through pharmacophore-guided design.
AID1334062Effect on JUN mRNA expression in human SH-SY5Y cells at EC10 by qPCR method relative to beta-actin2017Bioorganic & medicinal chemistry, 01-15, Volume: 25, Issue:2
Computer design, synthesis, and bioactivity analyses of drugs like fingolimod used in the treatment of multiple sclerosis.
AID1334058Effect on APP mRNA expression in human SH-SY5Y cells at EC10 by qPCR method relative to beta-actin2017Bioorganic & medicinal chemistry, 01-15, Volume: 25, Issue:2
Computer design, synthesis, and bioactivity analyses of drugs like fingolimod used in the treatment of multiple sclerosis.
AID1334160Effect on CCL2 mRNA expression in human SK-N-SH cells at EC10 by qPCR method relative to beta-actin2017Bioorganic & medicinal chemistry, 01-15, Volume: 25, Issue:2
Computer design, synthesis, and bioactivity analyses of drugs like fingolimod used in the treatment of multiple sclerosis.
AID1334052Effect on CD44 mRNA expression in human SH-SY5Y cells at EC10 by qPCR method relative to beta-actin2017Bioorganic & medicinal chemistry, 01-15, Volume: 25, Issue:2
Computer design, synthesis, and bioactivity analyses of drugs like fingolimod used in the treatment of multiple sclerosis.
AID1257232Immunosuppressive activity in mouse assessed as reduction of CD4+ level in peripheral blood assessed per 10'6 cells at 1.25 mg/kg, ip after 24 hrs by flow cytometry (Rvb = 0.73 +/- 0.07 ml)2015Bioorganic & medicinal chemistry letters, Nov-15, Volume: 25, Issue:22
New fluorinated agonists for targeting the sphingosin-1-phosphate receptor 1 (S1P(1)).
AID1422492Downregulation of CD98 expression in mouse FL5.12 cells at 10 uM after 3 hrs by DAPI staining-based FACS analysis relative to control2018European journal of medicinal chemistry, Nov-05, Volume: 159In search of constrained FTY720 and phytosphingosine analogs as dual acting anticancer agents targeting metabolic and epigenetic pathways.
AID1334220Effect on PIK3CG mRNA expression in human SK-N-SH cells at EC10 by qPCR method relative to beta-actin2017Bioorganic & medicinal chemistry, 01-15, Volume: 25, Issue:2
Computer design, synthesis, and bioactivity analyses of drugs like fingolimod used in the treatment of multiple sclerosis.
AID1300090Reduction in Ifit1 gene expression in SCID mouse with CD45RBhiCD4+ T-cell transfer-induced colitis model of inflammatory bowel disease at 5 mg/kg, po dosed every other day for 5 weeks by RT-PCR method2016ACS medicinal chemistry letters, Mar-10, Volume: 7, Issue:3
Identification and Preclinical Pharmacology of BMS-986104: A Differentiated S1P1 Receptor Modulator in Clinical Trials.
AID1334141Effect on S1PR1 mRNA expression in human U118MG cells at EC10 by qPCR method relative to beta-actin2017Bioorganic & medicinal chemistry, 01-15, Volume: 25, Issue:2
Computer design, synthesis, and bioactivity analyses of drugs like fingolimod used in the treatment of multiple sclerosis.
AID777395Cytotoxicity against Ph-negative human CCRF-CEM cells after 72 hrs by vital dye exclusion/flow cytometric analysis2013ACS medicinal chemistry letters, Oct-10, Volume: 4, Issue:10
Design, Synthesis, and Anti-leukemic Activity of Stereochemically Defined Constrained Analogs of FTY720 (Gilenya).
AID1334189Effect on EDNRA mRNA expression in human SK-N-SH cells at EC10 by qPCR method relative to beta-actin2017Bioorganic & medicinal chemistry, 01-15, Volume: 25, Issue:2
Computer design, synthesis, and bioactivity analyses of drugs like fingolimod used in the treatment of multiple sclerosis.
AID1185034Cytotoxicity against mouse MN9D cells assessed as metabolic activity at > 1.5 uM after 72 hrs by MTS assay2014ACS medicinal chemistry letters, Jul-10, Volume: 5, Issue:7
Novel FTY720-Based Compounds Stimulate Neurotrophin Expression and Phosphatase Activity in Dopaminergic Cells.
AID1334199Effect on MYC mRNA expression in human SK-N-SH cells at EC10 by qPCR method relative to beta-actin2017Bioorganic & medicinal chemistry, 01-15, Volume: 25, Issue:2
Computer design, synthesis, and bioactivity analyses of drugs like fingolimod used in the treatment of multiple sclerosis.
AID1334099Effect on CXCL10 mRNA expression in human U118MG cells at EC10 by qPCR method relative to beta-actin2017Bioorganic & medicinal chemistry, 01-15, Volume: 25, Issue:2
Computer design, synthesis, and bioactivity analyses of drugs like fingolimod used in the treatment of multiple sclerosis.
AID1334083Effect on AKT1 mRNA expression in human SH-SY5Y cells at EC10 by qPCR method relative to beta-actin2017Bioorganic & medicinal chemistry, 01-15, Volume: 25, Issue:2
Computer design, synthesis, and bioactivity analyses of drugs like fingolimod used in the treatment of multiple sclerosis.
AID1334204Effect on ADRB2 mRNA expression in human SK-N-SH cells at EC10 by qPCR method relative to beta-actin2017Bioorganic & medicinal chemistry, 01-15, Volume: 25, Issue:2
Computer design, synthesis, and bioactivity analyses of drugs like fingolimod used in the treatment of multiple sclerosis.
AID1730795AUC ratio in orally dosed cynomolgus monkey blood assessed as phosphate metabolite to parent compound2021Journal of medicinal chemistry, 02-11, Volume: 64, Issue:3
Bicyclic Ligand-Biased Agonists of S1P
AID1176664Reduction in ankle diameter in Lewis rat collagen-induced arthritis model at 1 mg/kg, po qd measured on day 17 (Rvb = +/- inches)2014ACS medicinal chemistry letters, Dec-11, Volume: 5, Issue:12
Discovery of APD334: Design of a Clinical Stage Functional Antagonist of the Sphingosine-1-phosphate-1 Receptor.
AID1300087Reduction in CD4 gene expression in SCID mouse with CD45RBhiCD4+ T-cell transfer-induced colitis model of inflammatory bowel disease at 5 mg/kg, po dosed every other day for 5 weeks by RT-PCR method2016ACS medicinal chemistry letters, Mar-10, Volume: 7, Issue:3
Identification and Preclinical Pharmacology of BMS-986104: A Differentiated S1P1 Receptor Modulator in Clinical Trials.
AID1334026Effect on CCL3 mRNA expression in human SH-SY5Y cells at EC10 by qPCR method relative to beta-actin2017Bioorganic & medicinal chemistry, 01-15, Volume: 25, Issue:2
Computer design, synthesis, and bioactivity analyses of drugs like fingolimod used in the treatment of multiple sclerosis.
AID1347412qHTS assay to identify inhibitors of the type 1 interferon - major histocompatibility complex class I in skeletal muscle: Counter screen cell viability and HiBit confirmation2020ACS chemical biology, 07-17, Volume: 15, Issue:7
High-Throughput Screening to Identify Inhibitors of the Type I Interferon-Major Histocompatibility Complex Class I Pathway in Skeletal Muscle.
AID1346986P-glycoprotein substrates identified in KB-3-1 adenocarcinoma cell line, qHTS therapeutic library screen2019Molecular pharmacology, 11, Volume: 96, Issue:5
A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
AID1346987P-glycoprotein substrates identified in KB-8-5-11 adenocarcinoma cell line, qHTS therapeutic library screen2019Molecular pharmacology, 11, Volume: 96, Issue:5
A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
AID1347411qHTS to identify inhibitors of the type 1 interferon - major histocompatibility complex class I in skeletal muscle: primary screen against the NCATS Mechanism Interrogation Plate v5.0 (MIPE) Libary2020ACS chemical biology, 07-17, Volume: 15, Issue:7
High-Throughput Screening to Identify Inhibitors of the Type I Interferon-Major Histocompatibility Complex Class I Pathway in Skeletal Muscle.
AID1347090qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for DAOY cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1296008Cytotoxic Profiling of Annotated Libraries Using Quantitative High-Throughput Screening2020SLAS discovery : advancing life sciences R & D, 01, Volume: 25, Issue:1
Cytotoxic Profiling of Annotated and Diverse Chemical Libraries Using Quantitative High-Throughput Screening.
AID1347094qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for BT-37 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347107qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh30 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347092qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for A673 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347097qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Saos-2 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347095qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for NB-EBc1 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347082qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lassa (LASV) Arenavirus: LASV Primary Screen - GLuc reporter signal2020Antiviral research, 01, Volume: 173A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1347098qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SK-N-SH cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347100qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for LAN-5 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1508591NCATS Rat Liver Microsome Stability Profiling2020Scientific reports, 11-26, Volume: 10, Issue:1
Retrospective assessment of rat liver microsomal stability at NCATS: data and QSAR models.
AID1347102qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh18 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347105qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for MG 63 (6-TG R) cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347108qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh41 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1508612NCATS Parallel Artificial Membrane Permeability Assay (PAMPA) Profiling2017Bioorganic & medicinal chemistry, 02-01, Volume: 25, Issue:3
Highly predictive and interpretable models for PAMPA permeability.
AID1347093qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SK-N-MC cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347091qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SJ-GBM2 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347103qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for OHS-50 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1508630Primary qHTS for small molecule stabilizers of the endoplasmic reticulum resident proteome: Secreted ER Calcium Modulated Protein (SERCaMP) assay2021Cell reports, 04-27, Volume: 35, Issue:4
A target-agnostic screen identifies approved drugs to stabilize the endoplasmic reticulum-resident proteome.
AID1347096qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for U-2 OS cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347083qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lassa (LASV) Arenavirus: Viability assay - alamar blue signal for LASV Primary Screen2020Antiviral research, 01, Volume: 173A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1347101qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for BT-12 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347099qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for NB1643 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347104qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for RD cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347086qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lymphocytic Choriomeningitis Arenaviruses (LCMV): LCMV Primary Screen - GLuc reporter signal2020Antiviral research, 01, Volume: 173A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1347089qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for TC32 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347154Primary screen GU AMC qHTS for Zika virus inhibitors2020Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49
Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID1347106qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for control Hh wild type fibroblast cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1745845Primary qHTS for Inhibitors of ATXN expression
AID1645848NCATS Kinetic Aqueous Solubility Profiling2019Bioorganic & medicinal chemistry, 07-15, Volume: 27, Issue:14
Predictive models of aqueous solubility of organic compounds built on A large dataset of high integrity.
AID1347163384 well plate NINDS AMC confirmatory qHTS for Zika virus inhibitors2020Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49
Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID1347153Confirmatory screen GU AMC qHTS for Zika virus inhibitors2020Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49
Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID1347168HepG2 cells viability qHTS for Zika virus inhibitors2020Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49
Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID1347156DAPI mCherry counterscreen qHTS for Zika virus inhibitors2020Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49
Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID1347149Furin counterscreen qHTS for Zika virus inhibitors2020Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49
Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID1347155Optimization screen NINDS Rhodamine qHTS for Zika virus inhibitors: Linked NS2B-NS3 protease assay2020Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49
Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID1347150Optimization screen NINDS AMC qHTS for Zika virus inhibitors: Linked NS2B-NS3 protease assay2020Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49
Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID1347167Vero cells viability qHTS for Zika virus inhibitors2020Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49
Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID1347151Optimization of GU AMC qHTS for Zika virus inhibitors: Unlinked NS2B-NS3 protease assay2020Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49
Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID1347152Confirmatory screen NINDS AMC qHTS for Zika virus inhibitors2020Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49
Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID1347169Tertiary RLuc qRT-PCR qHTS assay for Zika virus inhibitors2020Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49
Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID1347164384 well plate NINDS Rhodamine confirmatory qHTS for Zika virus inhibitors2020Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49
Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID1347161Confirmatory screen NINDS Rhodamine qHTS for Zika virus inhibitors2020Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49
Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID1347158ZIKV-mCherry secondary qHTS for Zika virus inhibitors2020Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49
Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID1346242Human S1P5 receptor (Lysophospholipid (S1P) receptors)2004Journal of medicinal chemistry, Dec-30, Volume: 47, Issue:27
A rational utilization of high-throughput screening affords selective, orally bioavailable 1-benzyl-3-carboxyazetidine sphingosine-1-phosphate-1 receptor agonists.
AID1346644Mouse TRPM7 (ChaK subfamily)2013British journal of pharmacology, Mar, Volume: 168, Issue:6
Sphingosine and FTY720 are potent inhibitors of the transient receptor potential melastatin 7 (TRPM7) channels.
AID1346535Mouse Kir3.4 (Inwardly rectifying potassium channels)2005American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons, Mar, Volume: 5, Issue:3
The heart rate decrease caused by acute FTY720 administration is mediated by the G protein-gated potassium channel I.
AID1346170Human S1P1 receptor (Lysophospholipid (S1P) receptors)2004Journal of medicinal chemistry, Dec-30, Volume: 47, Issue:27
A rational utilization of high-throughput screening affords selective, orally bioavailable 1-benzyl-3-carboxyazetidine sphingosine-1-phosphate-1 receptor agonists.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (65)

TimeframeStudies, This Drug (%)All Drugs %
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's10 (15.38)29.6817
2010's42 (64.62)24.3611
2020's13 (20.00)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 75.07

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be very strong demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index75.07 (24.57)
Research Supply Index4.19 (2.92)
Research Growth Index5.02 (4.65)
Search Engine Demand Index127.35 (26.88)
Search Engine Supply Index2.00 (0.95)

This Compound (75.07)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews6 (9.23%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other59 (90.77%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]